CA2593140C - Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) - Google Patents
Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) Download PDFInfo
- Publication number
- CA2593140C CA2593140C CA2593140A CA2593140A CA2593140C CA 2593140 C CA2593140 C CA 2593140C CA 2593140 A CA2593140 A CA 2593140A CA 2593140 A CA2593140 A CA 2593140A CA 2593140 C CA2593140 C CA 2593140C
- Authority
- CA
- Canada
- Prior art keywords
- acid
- nalbuphine
- peg
- ugt2b
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 50
- 239000003623 enhancer Substances 0.000 title abstract description 29
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title description 2
- 229940045145 uridine Drugs 0.000 title description 2
- NTKNGUAZSFAKEE-UHFFFAOYSA-N capillarisin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1OC1=CC=C(O)C=C1 NTKNGUAZSFAKEE-UHFFFAOYSA-N 0.000 claims abstract description 64
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 24
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims abstract description 24
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims abstract description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 22
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims abstract description 18
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims abstract description 18
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000011797 eriodictyol Nutrition 0.000 claims abstract description 18
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims abstract description 18
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 18
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 17
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 17
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960001587 hesperetin Drugs 0.000 claims abstract description 17
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 17
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims abstract description 16
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 15
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims abstract description 15
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000008714 apigenin Nutrition 0.000 claims abstract description 15
- 229940117893 apigenin Drugs 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 15
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 15
- -1 isoliquritigenin Chemical compound 0.000 claims abstract description 15
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims abstract description 14
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 claims abstract description 14
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 claims abstract description 14
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960005233 cineole Drugs 0.000 claims abstract description 14
- 229940045109 genistein Drugs 0.000 claims abstract description 14
- 235000006539 genistein Nutrition 0.000 claims abstract description 14
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract description 14
- MYXNWGACZJSMBT-VJXVFPJBSA-N isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MYXNWGACZJSMBT-VJXVFPJBSA-N 0.000 claims abstract description 14
- OYJCWTROZCNWAA-UHFFFAOYSA-N isovitexin Natural products OCC1OC(C(O)C(O)C1O)c2c(O)cc3CC(=CC(=O)c3c2O)c4ccc(O)cc4 OYJCWTROZCNWAA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000003839 salts Chemical group 0.000 claims abstract description 14
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 claims abstract description 14
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 12
- 239000012458 free base Substances 0.000 claims abstract description 12
- 229940099369 (+)- limonene Drugs 0.000 claims abstract description 11
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 claims abstract description 11
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 claims abstract description 11
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 claims abstract description 11
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims abstract description 11
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000008800 isorhamnetin Nutrition 0.000 claims abstract description 11
- 229940116411 terpineol Drugs 0.000 claims abstract description 11
- JRJGKUTZNBZHNK-UHFFFAOYSA-N 3-phenylpropyl acetate Chemical compound CC(=O)OCCCC1=CC=CC=C1 JRJGKUTZNBZHNK-UHFFFAOYSA-N 0.000 claims abstract description 10
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 10
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims abstract description 10
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims abstract description 10
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 10
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003321 baicalin Drugs 0.000 claims abstract description 10
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims abstract description 10
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 9
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940074391 gallic acid Drugs 0.000 claims abstract description 9
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 9
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 9
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 9
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 7
- 229920001992 poloxamer 407 Polymers 0.000 claims abstract description 7
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims abstract description 5
- OUGIDAPQYNCXRA-UHFFFAOYSA-N beta-naphthoflavone Chemical compound O1C2=CC=C3C=CC=CC3=C2C(=O)C=C1C1=CC=CC=C1 OUGIDAPQYNCXRA-UHFFFAOYSA-N 0.000 claims abstract 3
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 claims abstract 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 80
- 229960000805 nalbuphine Drugs 0.000 claims description 79
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 19
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 14
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 11
- 229960001736 buprenorphine Drugs 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 11
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims description 5
- BQJCRHHNABKAKU-XKUOQXLYSA-N (-)-Morphine Natural products O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@H]3CC5=CC=C4O BQJCRHHNABKAKU-XKUOQXLYSA-N 0.000 claims description 4
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 4
- 229960001410 hydromorphone Drugs 0.000 claims description 4
- 229960000938 nalorphine Drugs 0.000 claims description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 4
- 229960004127 naloxone Drugs 0.000 claims description 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 4
- 229960003086 naltrexone Drugs 0.000 claims description 4
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims description 4
- 229960005118 oxymorphone Drugs 0.000 claims description 4
- 229960004126 codeine Drugs 0.000 claims description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims 6
- 239000003814 drug Substances 0.000 abstract description 54
- 229940079593 drug Drugs 0.000 abstract description 51
- 150000001875 compounds Chemical class 0.000 abstract description 24
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 19
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 16
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 abstract description 14
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 abstract description 14
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract description 10
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 abstract description 10
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 abstract description 10
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 abstract description 9
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 abstract description 8
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 abstract description 8
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 abstract description 8
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 abstract description 8
- LUCQSVLCPJUJRN-UHVRHXOTSA-N Naringerin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)c1cc(O)c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c1 LUCQSVLCPJUJRN-UHVRHXOTSA-N 0.000 abstract description 8
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 abstract description 8
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 abstract description 8
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 8
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 8
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 abstract description 8
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 abstract description 8
- 229940015301 baicalein Drugs 0.000 abstract description 8
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 abstract description 8
- 229940100243 oleanolic acid Drugs 0.000 abstract description 8
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 abstract description 8
- 235000005875 quercetin Nutrition 0.000 abstract description 8
- 229960001285 quercetin Drugs 0.000 abstract description 8
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 abstract description 8
- 235000007246 (+)-epicatechin Nutrition 0.000 abstract description 7
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 abstract description 7
- ODBRNZZJSYPIDI-UHFFFAOYSA-N 3',4',5,7-tetrahydroxy-6-C-glucopyranosylflavone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-UHFFFAOYSA-N 0.000 abstract description 7
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 abstract description 7
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 abstract description 7
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 abstract description 7
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 abstract description 7
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 abstract description 7
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 abstract description 7
- 235000007240 daidzein Nutrition 0.000 abstract description 7
- 229940025878 hesperidin Drugs 0.000 abstract description 7
- ODBRNZZJSYPIDI-VJXVFPJBSA-N isoorientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-VJXVFPJBSA-N 0.000 abstract description 7
- UYJGIAWJIRZBNU-UHFFFAOYSA-N isoorientin Natural products OCC1OC(C(O)C(O)C1O)c2cc(O)c(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4 UYJGIAWJIRZBNU-UHFFFAOYSA-N 0.000 abstract description 7
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 abstract description 7
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 abstract description 7
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 abstract description 7
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 abstract description 7
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 abstract description 7
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 abstract description 6
- SDTOABMYDICPQU-UHFFFAOYSA-N Genkwanin Natural products C=1C(C)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 SDTOABMYDICPQU-UHFFFAOYSA-N 0.000 abstract description 6
- DZUKXCCSULKRJA-UHFFFAOYSA-N Isopratol Natural products C=1C(OC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 DZUKXCCSULKRJA-UHFFFAOYSA-N 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 6
- 238000001784 detoxification Methods 0.000 abstract description 6
- JPMYFOBNRRGFNO-UHFFFAOYSA-N genkwanin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 JPMYFOBNRRGFNO-UHFFFAOYSA-N 0.000 abstract description 6
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 abstract description 6
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 abstract description 6
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 abstract description 6
- 235000007625 naringenin Nutrition 0.000 abstract description 6
- 229940117954 naringenin Drugs 0.000 abstract description 6
- 229930013915 (+)-catechin Natural products 0.000 abstract description 5
- 235000007219 (+)-catechin Nutrition 0.000 abstract description 5
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 abstract description 5
- 235000007355 (-)-epicatechin Nutrition 0.000 abstract description 5
- 229930013783 (-)-epicatechin Natural products 0.000 abstract description 5
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 abstract description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 5
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 abstract description 5
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 abstract description 5
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 abstract description 5
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 abstract description 5
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 abstract description 5
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 abstract description 5
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 abstract description 5
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 abstract description 5
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 abstract description 5
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 abstract description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 5
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 abstract description 5
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 abstract description 5
- 235000008777 kaempferol Nutrition 0.000 abstract description 5
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 abstract description 5
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 abstract description 5
- 235000009498 luteolin Nutrition 0.000 abstract description 5
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 abstract description 5
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 abstract description 5
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 abstract description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 5
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 abstract description 5
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 abstract description 5
- 235000005493 rutin Nutrition 0.000 abstract description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 5
- 229960004555 rutoside Drugs 0.000 abstract description 5
- 229920001213 Polysorbate 20 Polymers 0.000 abstract description 4
- 229920001214 Polysorbate 60 Polymers 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract description 4
- 229920000053 polysorbate 80 Polymers 0.000 abstract description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 abstract description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 abstract description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 abstract description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 abstract description 3
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 abstract description 2
- SUTSVCLKBLJSPQ-UHFFFAOYSA-N luteolin 7-glucoside Natural products OC1C(O)C(O)C(CO)OC1C1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SUTSVCLKBLJSPQ-UHFFFAOYSA-N 0.000 abstract description 2
- 101100539374 Rattus norvegicus Ugt2b gene Proteins 0.000 abstract 2
- 108010075920 UDP-galactose translocator Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 27
- 239000000126 substance Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000001589 microsome Anatomy 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000004060 metabolic process Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000036267 drug metabolism Effects 0.000 description 10
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 7
- 239000000730 antalgic agent Substances 0.000 description 7
- 238000010579 first pass effect Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 6
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 6
- 241000628997 Flos Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 229960003951 masoprocol Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 101000841498 Homo sapiens UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 4
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 4
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960001338 colchicine Drugs 0.000 description 4
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 235000010576 Artemisia cina Nutrition 0.000 description 3
- 241001258832 Artemisia cina Species 0.000 description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 102100029819 UDP-glucuronosyltransferase 2B7 Human genes 0.000 description 3
- 101710200333 UDP-glucuronosyltransferase 2B7 Proteins 0.000 description 3
- 229940127381 UGT2B Inhibitors Drugs 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000023611 glucuronidation Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 2
- 244000081822 Uncaria gambir Species 0.000 description 2
- 241000055320 Viscum coloratum Species 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- ZIIAJIWLQUVGHB-UHFFFAOYSA-N cirsimaritin Chemical compound C=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 ZIIAJIWLQUVGHB-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 2
- 229960004352 diosmin Drugs 0.000 description 2
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229940127285 new chemical entity Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- HDJNEBJXWDVTNZ-UEBIAWITSA-N (1S,3R,6S,8R,11S,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(3S)-7-methyloct-1-en-3-yl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-ol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C=C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 HDJNEBJXWDVTNZ-UEBIAWITSA-N 0.000 description 1
- CNBHUROFMYCHGI-IEUUZZHOSA-N (23R,24S)-16beta,23:16alpha,24-diepoxy-9beta,19-cyclolanostane-3beta,15alpha,25-triol Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)[C@@H](O)[C@]2(O[C@@H]3C(C)(C)O)O[C@@H]3C[C@@H](C)[C@H]12 CNBHUROFMYCHGI-IEUUZZHOSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YPSSIDWEZCIQGA-UHFFFAOYSA-N 2-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxychromen-4-one Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(OC)=C(OC)C=C3C(=O)C=2)=C1 YPSSIDWEZCIQGA-UHFFFAOYSA-N 0.000 description 1
- SWINWPBPEKHUOD-UHFFFAOYSA-N 2-hydroxyestron Natural products OC1=C(O)C=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 SWINWPBPEKHUOD-UHFFFAOYSA-N 0.000 description 1
- SWINWPBPEKHUOD-JPVZDGGYSA-N 2-hydroxyestrone Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SWINWPBPEKHUOD-JPVZDGGYSA-N 0.000 description 1
- KWVIBDAKHDJCNY-UHFFFAOYSA-N 20alpha-atisine Natural products C12CCC3(C(C4=C)O)CCC4CC3C11CCCC2(C)CN2CCOC21 KWVIBDAKHDJCNY-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- TVFYDIBVHPZYML-UHFFFAOYSA-N Aglykon A Natural products C1C23CCC(O)C(C)(C)C3CCC(C3(C)C4=O)C21CCC3(C)C1C4OC(C(O)C(C)(C)O)CC1C TVFYDIBVHPZYML-UHFFFAOYSA-N 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- CNBHUROFMYCHGI-UHFFFAOYSA-N Cimicifugol Natural products C12CCC(C(C(O)CC3)(C)C)C43CC24CCC2(C)C1(C)C(O)C1(OC3C(C)(C)O)OC3CC(C)C21 CNBHUROFMYCHGI-UHFFFAOYSA-N 0.000 description 1
- BTPYUWOBZFGKAI-XYGBCAHESA-N Cimigenol 3-O-beta-D-xylopyranoside Chemical compound O([C@H]1CC[C@@]23[C@H](C1(C)C)CC[C@H]1[C@]4(C)[C@@H](O)[C@]56O[C@@H]([C@H](O6)C(C)(C)O)C[C@H]([C@@H]5[C@@]4(C)CC[C@]12C3)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O BTPYUWOBZFGKAI-XYGBCAHESA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102100034535 Histone H3.1 Human genes 0.000 description 1
- 101100112336 Homo sapiens CASP5 gene Proteins 0.000 description 1
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 description 1
- 101000640793 Homo sapiens UDP-galactose translocator Proteins 0.000 description 1
- 101000939535 Homo sapiens UDP-glucuronosyltransferase 2B10 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- MGTJNQWIXFSPLC-HQARQGIISA-N Jesaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=C(OC)C=C1 MGTJNQWIXFSPLC-HQARQGIISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102100029634 UDP-glucuronosyltransferase 2B10 Human genes 0.000 description 1
- 102100029633 UDP-glucuronosyltransferase 2B15 Human genes 0.000 description 1
- 101710200683 UDP-glucuronosyltransferase 2B15 Proteins 0.000 description 1
- 102100040373 UDP-glucuronosyltransferase 2B17 Human genes 0.000 description 1
- 101710200687 UDP-glucuronosyltransferase 2B17 Proteins 0.000 description 1
- 102100029785 UDP-glucuronosyltransferase 2B4 Human genes 0.000 description 1
- 101710200334 UDP-glucuronosyltransferase 2B4 Proteins 0.000 description 1
- 108091008114 UGT1A2P Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- VSRVRBXGIRFARR-OUEGHFHCSA-N alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O VSRVRBXGIRFARR-OUEGHFHCSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- BTPYUWOBZFGKAI-UHFFFAOYSA-N cimiracemoside C Natural products C1C23CCC4(C)C5C(C)CC(C(O6)C(C)(C)O)OC56C(O)C4(C)C2CCC(C2(C)C)C31CCC2OC1OCC(O)C(O)C1O BTPYUWOBZFGKAI-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- FRLSLRCKTJDTNW-UHFFFAOYSA-N cirsilineol Natural products COc1c(C)cc2OC(=CC(=O)c2c1O)c3ccc(O)c(C)c3 FRLSLRCKTJDTNW-UHFFFAOYSA-N 0.000 description 1
- OBQMAEGCYPFNKQ-UHFFFAOYSA-N cirsimaritin Natural products COc1c(C)cc2OC(=CC(=O)c2c1O)c3ccc(O)cc3 OBQMAEGCYPFNKQ-UHFFFAOYSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- TVFYDIBVHPZYML-PIHBKODKSA-N dahurinol Chemical compound C([C@]12C3)C[C@H](O)C(C)(C)[C@@H]2CC[C@@H]([C@]2(C)C4=O)[C@@]13CC[C@]2(C)[C@@H]1[C@H]4O[C@@H]([C@@H](O)C(C)(C)O)C[C@H]1C TVFYDIBVHPZYML-PIHBKODKSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940125380 highly variable drug Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- MGTJNQWIXFSPLC-UHFFFAOYSA-N jesaconitine Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=C(OC)C=C1 MGTJNQWIXFSPLC-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- XUHJBXVYNBQQBD-UHFFFAOYSA-N mesaconitine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(OC(C)=O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XUHJBXVYNBQQBD-GQPWXMLZSA-N molport-002-525-145 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-GQPWXMLZSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
- 229950008687 oltipraz Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000009835 oxypaeoniflora Chemical class 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical class C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Chemical class OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- KWVIBDAKHDJCNY-PTRUQLRHSA-N v81k1mmx3x Chemical compound C([C@]1([C@@H](C2=C)O)CC[C@H]34)C[C@H]2C[C@H]1[C@]41CCC[C@@]3(C)CN2CCO[C@H]21 KWVIBDAKHDJCNY-PTRUQLRHSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A UGT2B inhibitor capable of increasing the bio-availability of a drug, which is a compound in a free base or a pharmaceutically acceptable salt form and which is selected from the group consisting of: capillarisin, isorhamnetin .beta.-naphthoflavone, .alpha.-naphthoflavone, hesperetin, terpineol, (+)-limonene, .beta.-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, terpineol, (+)-limonene, .beta.-myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, PEG
(Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ ® 58, BRIJ ® 76, Pluronic® F68 , Pluronic ® F127, and a combination thereof.
A UGT2B enhancer capable of enhancing the liver detoxification function in a subject, which is a compound in a free base or a pharmaceutically acceptable salt form and which is selected from the group consisting of: mordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof
(Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ ® 58, BRIJ ® 76, Pluronic® F68 , Pluronic ® F127, and a combination thereof.
A UGT2B enhancer capable of enhancing the liver detoxification function in a subject, which is a compound in a free base or a pharmaceutically acceptable salt form and which is selected from the group consisting of: mordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof
Description
INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) BACKGROUND OF THE INVENTION
1. Field of the invention This invention aims at enhancing drug bio-availability by providing an effective UGT2B inhibitor as well as a UGT2B enhancer for increasing the detoxification ability of individuals.
1. Field of the invention This invention aims at enhancing drug bio-availability by providing an effective UGT2B inhibitor as well as a UGT2B enhancer for increasing the detoxification ability of individuals.
2. Description of the prior art The drug metabolism process in human body, especially the metabolism of high fat-soluble drugs, includes two biotransformation steps: phase I reaction that catalyzes fat-soluble molecules to polarized molecules, and phase II reaction that produces highly polarized molecule through conjugation, such that the drugs can be metabolized efficiently and excreted to urine or feces.
The most common and important conjugation is glucuronidation by uridine diphosphate ( UDP ) -glucuronosyltransferases (refers to as UGTs , EC 2.4.1.17 hereafter).
The UGTs is one of the major enzymes in phase II reaction in human. It is now evident that UGTs have more than 110 isoenzymes. UGTs can catalyze the conjugation of UDP-glucuronic acid (UDPGA) and the endogenous fat-soluble compounds' chemical bonds, such as hydroxyl, sulfonyl, carboxylic acid, amine, or amide, to facilitate the 0-glucuronidation, N-glucuronidation, or S-glucuronidation (King et al., 2000, Cuff. Drug Metab., 1(2): 143-61), and thus enhances the polarity of the fat-soluble molecules.
According to a review article published by Radominska-Pandya et al (Drug Metab Rev. 31(4):817-99, 1999), most human UGTs belong to the UGT1A and UGT2B families. The UGT1A family consists of UGT1A1, UGT1A2P, UGT1A3-10, UGTIA1 1P and UGT1Al2p, while UGT2B family consists of UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17.
In addition, UGTs posses extensive substrate specificity. The UGT1A and UGT2B metabolize different compounds. The UGT1A family mainly metabolizes phenolic compounds such as estrone, 2-hydroxyestrone, 4-nitrophenol, 1-naphthol, etc. with the involvement of bilirubin. The UGT2B family metabolizes steroid compounds such as androsterone, linoleic acid, etc. with the involvement of bile acids.
It was reported that UGTs can either enhance the bio-activity of some compounds or, under certain circumstances, transform some compound into toxic substances, such as morphine, steroids, bile acids and mid retinoids. (see Vore et al. (1983a) Life Sciences 32:2989-2993; Vore et al. (1983b) Drug Metabolism Reviews 14:1005-1019 ; Abbott and Palmour (1988) Life Sciences 43:1685-169).
It was also reported that UGTs have involved in the activation of polycyclic aromatic hydrocarbons (PAH) and heterocyclic aromatic amines. (Munzel et al.
(1996) Archives of Biochemistry and Biophysics, 355: 205-210; Bock et al.
(1998) Advances in Enzyme Regulation, 38: 207-222).
UGTs can be found in several tissues including liver, kidney, bile duct, esophagus, stomach, intestine, rectum, ileum, jejunum, spleen, mammary gland, skin, lung, and brain. However, the distribution of various UGTs in human body differs by type. For instance, UGT2B7 exists mainly in esophagus, liver, intestine, colon, kidney, and spleen; while UGT1A1 can be found in liver, bile duct, stomach and colon ( Tukey et al. (2000) Annu. Rev. Pharmacol. Toxicol., 40:
581-616. Review ) .
Studies by Burchell and Coughtrie (Burchell B and Coughtrie MW (1997) Environmental Health Perspectives 105: 739-747) found differences among individuals in their abilities to metabolize medicines, due to the genetic polymorphisms in UGT genes. Therefore, the information regarding the regulatory function of UGTs in individual's drug metabolism process is essential in evaluating a drug's potential pharmaceutical efficacy and its interaction with other drugs.
The UGTs is also an important detoxification system in human body. In addition to the endogenous fat-soluble compounds, the exogenous fat-soluble compounds can also become water-soluble through glucuronidation, and thus enhances the excretion of the exogenous fat-soluble compounds and maintains human body's normal detoxification function.
Therefore, the glucuronidation will be hampered by defected UGTs activities in individuals who suffered from liver diseases. Consequently, the liver's lower clearance rate in metabolizing drug will increase the toxic reaction and the rate of carcinogenesis in an individual with liver diseases.
According to literatures, butylated hydroxyanisole (BHA) (Buetler et al.
(1995) Toxicology & Applied Pharmacology 135(1): 45-57) and pregnenolone-16 a -carbonitrile (PCN) (Viollon-Abadie et al., 1999, Toxicology & Applied Pharmacology., 155(1):1-12) may activate UGT2B.
Before circulating through the entire body, most drugs that are absorbable to gastroenterological tract will enter the liver through portal circulation.
This is the so-called "first-pass effect". It had been confirmed that the ubiquitous UGTs
The most common and important conjugation is glucuronidation by uridine diphosphate ( UDP ) -glucuronosyltransferases (refers to as UGTs , EC 2.4.1.17 hereafter).
The UGTs is one of the major enzymes in phase II reaction in human. It is now evident that UGTs have more than 110 isoenzymes. UGTs can catalyze the conjugation of UDP-glucuronic acid (UDPGA) and the endogenous fat-soluble compounds' chemical bonds, such as hydroxyl, sulfonyl, carboxylic acid, amine, or amide, to facilitate the 0-glucuronidation, N-glucuronidation, or S-glucuronidation (King et al., 2000, Cuff. Drug Metab., 1(2): 143-61), and thus enhances the polarity of the fat-soluble molecules.
According to a review article published by Radominska-Pandya et al (Drug Metab Rev. 31(4):817-99, 1999), most human UGTs belong to the UGT1A and UGT2B families. The UGT1A family consists of UGT1A1, UGT1A2P, UGT1A3-10, UGTIA1 1P and UGT1Al2p, while UGT2B family consists of UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17.
In addition, UGTs posses extensive substrate specificity. The UGT1A and UGT2B metabolize different compounds. The UGT1A family mainly metabolizes phenolic compounds such as estrone, 2-hydroxyestrone, 4-nitrophenol, 1-naphthol, etc. with the involvement of bilirubin. The UGT2B family metabolizes steroid compounds such as androsterone, linoleic acid, etc. with the involvement of bile acids.
It was reported that UGTs can either enhance the bio-activity of some compounds or, under certain circumstances, transform some compound into toxic substances, such as morphine, steroids, bile acids and mid retinoids. (see Vore et al. (1983a) Life Sciences 32:2989-2993; Vore et al. (1983b) Drug Metabolism Reviews 14:1005-1019 ; Abbott and Palmour (1988) Life Sciences 43:1685-169).
It was also reported that UGTs have involved in the activation of polycyclic aromatic hydrocarbons (PAH) and heterocyclic aromatic amines. (Munzel et al.
(1996) Archives of Biochemistry and Biophysics, 355: 205-210; Bock et al.
(1998) Advances in Enzyme Regulation, 38: 207-222).
UGTs can be found in several tissues including liver, kidney, bile duct, esophagus, stomach, intestine, rectum, ileum, jejunum, spleen, mammary gland, skin, lung, and brain. However, the distribution of various UGTs in human body differs by type. For instance, UGT2B7 exists mainly in esophagus, liver, intestine, colon, kidney, and spleen; while UGT1A1 can be found in liver, bile duct, stomach and colon ( Tukey et al. (2000) Annu. Rev. Pharmacol. Toxicol., 40:
581-616. Review ) .
Studies by Burchell and Coughtrie (Burchell B and Coughtrie MW (1997) Environmental Health Perspectives 105: 739-747) found differences among individuals in their abilities to metabolize medicines, due to the genetic polymorphisms in UGT genes. Therefore, the information regarding the regulatory function of UGTs in individual's drug metabolism process is essential in evaluating a drug's potential pharmaceutical efficacy and its interaction with other drugs.
The UGTs is also an important detoxification system in human body. In addition to the endogenous fat-soluble compounds, the exogenous fat-soluble compounds can also become water-soluble through glucuronidation, and thus enhances the excretion of the exogenous fat-soluble compounds and maintains human body's normal detoxification function.
Therefore, the glucuronidation will be hampered by defected UGTs activities in individuals who suffered from liver diseases. Consequently, the liver's lower clearance rate in metabolizing drug will increase the toxic reaction and the rate of carcinogenesis in an individual with liver diseases.
According to literatures, butylated hydroxyanisole (BHA) (Buetler et al.
(1995) Toxicology & Applied Pharmacology 135(1): 45-57) and pregnenolone-16 a -carbonitrile (PCN) (Viollon-Abadie et al., 1999, Toxicology & Applied Pharmacology., 155(1):1-12) may activate UGT2B.
Before circulating through the entire body, most drugs that are absorbable to gastroenterological tract will enter the liver through portal circulation.
This is the so-called "first-pass effect". It had been confirmed that the ubiquitous UGTs
3 in the intestine and the liver is one of the major enzymes that are necessary to the "first-pass effect" of the drug absorbance process. Such "first-pass effect"
will stabilize a drug's bio-availability.
Owing to this phenomenon, the pharmacological scientists are aggressively looking for safe, effective, and reversible UGT inhibitors to apply to drugs with low bio-availability due to their fast metabolism, for the purpose of increasing their efficacy. Such a need is especially evident in oral medicines.
Studies in UGT inhibitors and their interactions with drugs have been conducted in recent year. Reported UGT inhibitors include silymarin (Venkataramanan et al. 2000, Drug Metabolism and Disposition 28: 1270-1273), quinoline (Dong et al., 1999, Drug Metabolism & Disposition 27:1423-1428), oltipraz (Vargas et al., 1998, Drug Metabolism & Disposition 26:91-97), tacrolimus (Zucker et al., 1999, Therapeutic Drug Monitoring 21:35-43), octyl gallate, apigenin, imipramine, clozapine, acetaminophen, and emodin (Radominska-Pandya et al., 1999, as mentioned earlier).
It was also reported that diazepam and flunitrazepam (FM2) can strongly inhibit the activity of UGT2B (Grancharov et al., 2001, harmacol Ther.,89(2):171-86).
Since the aforementioned UGT inhibitors are active drug ingredients by themselves and will induce prominent physical responses, they are not good candidates as drug absorption enhancers.
It was well recognized among those who are familiar with the techniques that a good UGT inhibitor for enhancing the bio-availability of drugs should at least posses the following three characteristics: (1) No or minimum pharmacological effect, except inhibiting UGT; (2) The inhibition should be
will stabilize a drug's bio-availability.
Owing to this phenomenon, the pharmacological scientists are aggressively looking for safe, effective, and reversible UGT inhibitors to apply to drugs with low bio-availability due to their fast metabolism, for the purpose of increasing their efficacy. Such a need is especially evident in oral medicines.
Studies in UGT inhibitors and their interactions with drugs have been conducted in recent year. Reported UGT inhibitors include silymarin (Venkataramanan et al. 2000, Drug Metabolism and Disposition 28: 1270-1273), quinoline (Dong et al., 1999, Drug Metabolism & Disposition 27:1423-1428), oltipraz (Vargas et al., 1998, Drug Metabolism & Disposition 26:91-97), tacrolimus (Zucker et al., 1999, Therapeutic Drug Monitoring 21:35-43), octyl gallate, apigenin, imipramine, clozapine, acetaminophen, and emodin (Radominska-Pandya et al., 1999, as mentioned earlier).
It was also reported that diazepam and flunitrazepam (FM2) can strongly inhibit the activity of UGT2B (Grancharov et al., 2001, harmacol Ther.,89(2):171-86).
Since the aforementioned UGT inhibitors are active drug ingredients by themselves and will induce prominent physical responses, they are not good candidates as drug absorption enhancers.
It was well recognized among those who are familiar with the techniques that a good UGT inhibitor for enhancing the bio-availability of drugs should at least posses the following three characteristics: (1) No or minimum pharmacological effect, except inhibiting UGT; (2) The inhibition should be
4 reversible. In other words, UGTs should be able to restore its normal functions, after the inhibitors were excreted or metabolized; and (3) The efficacy of the inhibitor should be able to prominently lower the activity of UGTs in the intestine and the liver with a minimum dose.
It was known in recent years that grapefruit juice and certain components of other natural products, such as narigin, naringenin, hesperidine and other flavonoids, can inhibit some pharmacological activities.
US 6,121,23 depicts that by using essential oil, one can enhance the bio-availability of an oral medicine in the intestine of a mammal. The method involves co-administration of a therapeutic dose of the pharmaceutical compound and an essential oil or a component of essential oil where 10% inhibition was demonstrated with the presence of no more than 0.01 wt. of essential oil or a component of essential oil. In this US patent, it was also demonstrated that essential oil enhances the bio-availability of the drug through its inhibition of cytochrome P450.
Another study indicated that flavonoids compounds prepared from the liver of Long-Evants rat, such as naringenin, hesperetin, kaempferol, quercetin, rutin, flavone, a-naphthoflavone, and 13-naphthoflavone can inhibit the metabolism of estrone and estradiol in microsomes (Zhu et al. 1998, J Steroid Biochem Mol Bio1,64(3-4) : 207-15).
According to Chinese herbal medicine literature, due to its relatively milder toxicity than synthetic compounds, Chinese herbal enhancers (CHEs) were widely used in about 30%-75% of Chinese herbal medicine prescriptions. According to Japan's Food and Drug Administration, among 210 official Chinese herbal compound prescriptions, Glycyrrhizae radix is the most frequently used CHE (in
It was known in recent years that grapefruit juice and certain components of other natural products, such as narigin, naringenin, hesperidine and other flavonoids, can inhibit some pharmacological activities.
US 6,121,23 depicts that by using essential oil, one can enhance the bio-availability of an oral medicine in the intestine of a mammal. The method involves co-administration of a therapeutic dose of the pharmaceutical compound and an essential oil or a component of essential oil where 10% inhibition was demonstrated with the presence of no more than 0.01 wt. of essential oil or a component of essential oil. In this US patent, it was also demonstrated that essential oil enhances the bio-availability of the drug through its inhibition of cytochrome P450.
Another study indicated that flavonoids compounds prepared from the liver of Long-Evants rat, such as naringenin, hesperetin, kaempferol, quercetin, rutin, flavone, a-naphthoflavone, and 13-naphthoflavone can inhibit the metabolism of estrone and estradiol in microsomes (Zhu et al. 1998, J Steroid Biochem Mol Bio1,64(3-4) : 207-15).
According to Chinese herbal medicine literature, due to its relatively milder toxicity than synthetic compounds, Chinese herbal enhancers (CHEs) were widely used in about 30%-75% of Chinese herbal medicine prescriptions. According to Japan's Food and Drug Administration, among 210 official Chinese herbal compound prescriptions, Glycyrrhizae radix is the most frequently used CHE (in
5 150 or 71.4% prescriptions), followed by Zingiberis (in 42.9% prescriptions) and Zizyphi fructus (in 31.9% prescriptions). In the Japanese National Formulary (2nd Edition), the most frequently used CHEs are Glycyrrhizae radix (71.4%), Zingiberis (42.9%), Holen (poria) (35.2%), Paeoniae radix (32.9%), Zizyphi fructus (31.9%) and Cinnamami cortex (29.5%).
Other than these frequently used CHEs, studies regarding other CHEs are rare. For the purpose of developing new UGT inhibitors, further investigations on some other CHEs are worthwhile. For instance, flavonoids-containing CHEs like Scutellariae radix (contains baicalin, wogonin, baicalein, skullcap-flavon I
and wogoin glucuronide), Artemisiae cpillaris herba (contains capillarisin, cirsilineol, cirsimaritin, genkwanin, rhamrcocitrin); and terpenoids-containing CHEs like Alismatis rhizome (contains alisol monoacetate and triterpenoids), Moutan radicis cortex (contains paeoniflorin, oxypaeoniflorin and its benzoyl derivatives), Aconiti tuber (contains aconitine, mesaconitine, jesaconitine and atisine), Tragacantha (contains tragoside I and tragoside II), Persical semen (contains methylenecycloartanol), Cimicifugae rhizome (contains cimigenol, cimigenol xyloside and its 12-hydroxyl derivatives and dahurinol).
Possible mechanisms of CHEs as enhancers of drug absorption include: (1) catalysts: new active ingredients may be derived from the cooking or the preparation process of Chinese herbal medicine; (2) carrier: carrying the drug's active ingredients going through barriers to reach its targets; (3) enzyme inhibitor:
take UGT inhibitor as an example, if a drug's active ingredients cannot be absorbed by oral administration due to UGT metabolism, it may become orally absorbable by combining with a CHEs that lowers or restricts the "first-pass effect".
Other than these frequently used CHEs, studies regarding other CHEs are rare. For the purpose of developing new UGT inhibitors, further investigations on some other CHEs are worthwhile. For instance, flavonoids-containing CHEs like Scutellariae radix (contains baicalin, wogonin, baicalein, skullcap-flavon I
and wogoin glucuronide), Artemisiae cpillaris herba (contains capillarisin, cirsilineol, cirsimaritin, genkwanin, rhamrcocitrin); and terpenoids-containing CHEs like Alismatis rhizome (contains alisol monoacetate and triterpenoids), Moutan radicis cortex (contains paeoniflorin, oxypaeoniflorin and its benzoyl derivatives), Aconiti tuber (contains aconitine, mesaconitine, jesaconitine and atisine), Tragacantha (contains tragoside I and tragoside II), Persical semen (contains methylenecycloartanol), Cimicifugae rhizome (contains cimigenol, cimigenol xyloside and its 12-hydroxyl derivatives and dahurinol).
Possible mechanisms of CHEs as enhancers of drug absorption include: (1) catalysts: new active ingredients may be derived from the cooking or the preparation process of Chinese herbal medicine; (2) carrier: carrying the drug's active ingredients going through barriers to reach its targets; (3) enzyme inhibitor:
take UGT inhibitor as an example, if a drug's active ingredients cannot be absorbed by oral administration due to UGT metabolism, it may become orally absorbable by combining with a CHEs that lowers or restricts the "first-pass effect".
6 This application's inventor found that glycyrrhizin in Glycyrrhizae radix and oleanolic acid and P-myrcene in Zizyphi fructus can enhance the partition coefficient in drugs like acyclovir, buprenorphine, or buprenorphine and hence increase these drug's transdermal permeation more than 1,000 percent in either in vitro or clinical trials. Reference: Dr. Oliver Yoa-Pu Hu's acyclovir Patent (Taiwan Patent No.084682, US Patent No.6,162,459, Japan Patent No.2681881);
buprenorphine Patent (Taiwan Patent No.137835, US Patent No.6,004,969); and piroxi cam Patent (Taiwan Patent No.133855).
New opiods drugs such as buprenorphine, nalbuphine and butorphanol were developed recently. They are classified as narcotic agonist-antagonist analgesics, due to their dual agonistic and antagonistic effects on opiods-receptors (Schmidt, W.K. et al, Drug Alcohol Depend. 14, 339, 1985). In addition to having high affinity to opiods-receptors, these dual-effect drugs can also be used as an antagonist to compensate for the drawbacks of narcotic analgesics, such as to lower their addictive effect and to drastically minimize their respiratory inhibition.
According to Schmidt et al (1985), nalbuphine possesses both the affinity to Kappa receptor (0P2) and the antagonist effect to Mu receptor (0P3). There is no obvious addiction or synergistic effect with only a slight respiratory inhibition, after a six-month continuous usage of nalbuphine. Therefore, in clinical trials, nalbuphine is safer than the traditional narcotic analgesics, and has exhibited an excellent therapeutic effect.
The drawback of this drug is its poor absorbability when delivered orally.
In Goodman and Gillman's study, the bio-availability of nalbuphine is 11 4 %, while the bio-availability of nalbuphine in animal is 2.7 0.4%, a shorter half-life.
In current clinical pharmacology, the drug can only be administered through IV,
buprenorphine Patent (Taiwan Patent No.137835, US Patent No.6,004,969); and piroxi cam Patent (Taiwan Patent No.133855).
New opiods drugs such as buprenorphine, nalbuphine and butorphanol were developed recently. They are classified as narcotic agonist-antagonist analgesics, due to their dual agonistic and antagonistic effects on opiods-receptors (Schmidt, W.K. et al, Drug Alcohol Depend. 14, 339, 1985). In addition to having high affinity to opiods-receptors, these dual-effect drugs can also be used as an antagonist to compensate for the drawbacks of narcotic analgesics, such as to lower their addictive effect and to drastically minimize their respiratory inhibition.
According to Schmidt et al (1985), nalbuphine possesses both the affinity to Kappa receptor (0P2) and the antagonist effect to Mu receptor (0P3). There is no obvious addiction or synergistic effect with only a slight respiratory inhibition, after a six-month continuous usage of nalbuphine. Therefore, in clinical trials, nalbuphine is safer than the traditional narcotic analgesics, and has exhibited an excellent therapeutic effect.
The drawback of this drug is its poor absorbability when delivered orally.
In Goodman and Gillman's study, the bio-availability of nalbuphine is 11 4 %, while the bio-availability of nalbuphine in animal is 2.7 0.4%, a shorter half-life.
In current clinical pharmacology, the drug can only be administered through IV,
7 not orally. The nalbuphine's pharmacokinetic studies indicate its half life through the excretion of liver is 5 hours, and about 7% of the drug are excreted to the urine in its original form (Birgit et al. 1996, Drug metabolism and Disposition, 25(1):1-4; Birgit et al. 1998, Drug Metabolism and Disposition, 26(1):73-77; and Richard et al. 1990, Clin. Pharmacol Ther., 47:12-19).
Published literature has proved that nalbuphine is mainly metabolized through UGT2B7 (Radominska-Pandya et al., 1999).
US 6,004,969 depicts a transdermal delivery of buprenorphine. The method includes the delivery of a drug to patients that contains the following pharmaceutical ingredients: 1) about 0.8% of buprenorphine or its HC1 salt; 2) about 10-20% of one or a combination of the following drug enhancers: 2-pinene, trans-cinnamic acid, 13-myrcene or 13-myrcene; and 3) about 79.2-89.2% of one or a combination of the following inert ingredients: stearyl alcohol, sodium carboxymethyl-cellulose, glycerol, cetyl alcohol, 1,3-propylene glycol, and water.
Studies regarding the use of Chinese herbal medicine in diseases treatment and prevention have become prominent in recent years. However, the issues about what are the herbal medicines that can inhibit UGT and how to apply them to the UGT-related therapeutic usages are still need to be addressed.
Besides, there are a lot of studies indicate that many pharmaceutical excipients might have effect on the activity of cytochrome P450. It is thought generally that most of the excipients are used to increase the volume, the solubility or stability and so on of drugs. However, such point of view might need to be changed.
Mountfield et al. (Mountfield et al.,2000) indicates at 2000 that some of the excipients influence CYP3A4 enzyme activity in microsomal enzyme experiment
Published literature has proved that nalbuphine is mainly metabolized through UGT2B7 (Radominska-Pandya et al., 1999).
US 6,004,969 depicts a transdermal delivery of buprenorphine. The method includes the delivery of a drug to patients that contains the following pharmaceutical ingredients: 1) about 0.8% of buprenorphine or its HC1 salt; 2) about 10-20% of one or a combination of the following drug enhancers: 2-pinene, trans-cinnamic acid, 13-myrcene or 13-myrcene; and 3) about 79.2-89.2% of one or a combination of the following inert ingredients: stearyl alcohol, sodium carboxymethyl-cellulose, glycerol, cetyl alcohol, 1,3-propylene glycol, and water.
Studies regarding the use of Chinese herbal medicine in diseases treatment and prevention have become prominent in recent years. However, the issues about what are the herbal medicines that can inhibit UGT and how to apply them to the UGT-related therapeutic usages are still need to be addressed.
Besides, there are a lot of studies indicate that many pharmaceutical excipients might have effect on the activity of cytochrome P450. It is thought generally that most of the excipients are used to increase the volume, the solubility or stability and so on of drugs. However, such point of view might need to be changed.
Mountfield et al. (Mountfield et al.,2000) indicates at 2000 that some of the excipients influence CYP3A4 enzyme activity in microsomal enzyme experiment
8 in vitro. Some other excipients are also reported in other researches, for example, PEG400 (Johnson et al., 2003), CremophorTm RH40(Wabdel et al., 2003) both have effect on the enzyme activity of CYP3A4.
Bravo et al. (Bravo et al., 2003) have studied the effect of surfactant on activity of enzyme. The medicine studied is colchicine that is metabolized by P-gp and CYP3A4 in vivo. The control group is colchicine dissolved in 0.9% NaC1 solution, and the experimental group is colchicine dissolved in 5% solutol NaC1 solution. The result shows that the concentration of experimental group is above two times of controlled group. The clearing rate of experimental group is obviously two folds lower than controlled group. And in-vitro hepatocyte experiment shows that 0.003% solutol HS15 inhibits clearing rate of colchicine. It is worth noted that this kind of surfactants are thought to destroy cell membrane in other studies, affect metabolism of cell (Silva et al., 2004), change the usage of co-factor in catalysis reaction of enzymes or interaction between substrate and enzyme. However, there is no evidence showing that solutol HS15 at such concentration has any impact on the intact of the cell under light microscope.
Therefore, the detailed mechanism needs to be investigated in the future.
Generally speaking, the research and development of new medicine could be divided into several stages: New Chemical Entity (NCE), pre-clinical toxicity testing, pharmacological testing and finally, the clinical testing.
Traditional chemical selection is to modify the structure on those who has pharmacological activity or extract the biological chemicals from plants. Unfortunately, most of these chemicals are fat-soluble compound, thus, different excipients are added to improve solubility and stability of these chemicals. For pharmaceutical industry, it is inevitable to use excipient. Hence, this invention not only studies the effect of
Bravo et al. (Bravo et al., 2003) have studied the effect of surfactant on activity of enzyme. The medicine studied is colchicine that is metabolized by P-gp and CYP3A4 in vivo. The control group is colchicine dissolved in 0.9% NaC1 solution, and the experimental group is colchicine dissolved in 5% solutol NaC1 solution. The result shows that the concentration of experimental group is above two times of controlled group. The clearing rate of experimental group is obviously two folds lower than controlled group. And in-vitro hepatocyte experiment shows that 0.003% solutol HS15 inhibits clearing rate of colchicine. It is worth noted that this kind of surfactants are thought to destroy cell membrane in other studies, affect metabolism of cell (Silva et al., 2004), change the usage of co-factor in catalysis reaction of enzymes or interaction between substrate and enzyme. However, there is no evidence showing that solutol HS15 at such concentration has any impact on the intact of the cell under light microscope.
Therefore, the detailed mechanism needs to be investigated in the future.
Generally speaking, the research and development of new medicine could be divided into several stages: New Chemical Entity (NCE), pre-clinical toxicity testing, pharmacological testing and finally, the clinical testing.
Traditional chemical selection is to modify the structure on those who has pharmacological activity or extract the biological chemicals from plants. Unfortunately, most of these chemicals are fat-soluble compound, thus, different excipients are added to improve solubility and stability of these chemicals. For pharmaceutical industry, it is inevitable to use excipient. Hence, this invention not only studies the effect of
9 using CHEs as UGT inhibitor and enhancer, but also the effect of excipients on enzyme activity of UGT in order to provide more UGT inhibitors and enhancers that are safe and effective.
In sum, the development of a safe, effective and reversible UGT inhibitor will enable the oral administration of high "first-pass effect" drugs, and will minimize the side effect and the dosage of highly variable drugs. In addition, the toxicity of the carcinogenic compounds caused by UGT activities can also be reduced.
Developing a safe, efficient and reversible UGT enhancer is also a desirable goal of the pharmaceutical industry. It will help patients with low clearance rate in drug metabolism due to reduced liver functions to metabolize the drugs, and enhance the detoxification function of the liver.
SUMMARY OF THE INVENTION
First of all, this invention provides a UGT2B inhibitor that can increase the bio-availability of drugs. This inhibitor is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of:
capillarisin, isorhamnetin, 13-naphthoflavone, a-naphthoflavone, hesperetin, terpineol, (+)-limonene, P-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, terpineol, (+)-limonene, myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, TweenTm 20, TweenTm 60, TweenTm 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a combination thereof.
This invention also provides a pharmaceutical composition that includes the aforementioned UGT2B inhibitor as its active ingredient, and a pharmaceutically acceptable inert ingredient. The pharmaceutical composition in this invention can decrease the enzymatic activity of UGT2B, and thus increase the bio-availability of analgesics such as morphine.
Secondly, this invention provides an UGT2B enhancer that can improve the detoxification function of the liver. This enhancer is a compound with a free base or a pharmaceutically acceptable salt comprises of selected materials from the following: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, uteolin-7-glucoside, egosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, and trans-cinnamaldehyde.
This invention also provides a pharmaceutical composition that includes the aforementioned UGT2B enhancer as its active ingredient, and a pharmaceutically acceptable inert ingredient. The pharmaceutical composition in this invention can increase the enzymatic activity of UGT2B, and thus increase the clearance rate of a drug.
According to an aspect, the invention provides for a pharmaceutical composition comprising: an opioid; an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, fl-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, puerarin, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, polyethylene glycol (PEG) 400, PEG 2000, PEG 4000, Tween0 20, Tweent 60, Tween0 80, BRIJ 58, BRIJ 76, Pluronic0 F68, Pluronic0 F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
According to another aspect, the invention provides for a pharmaceutical composition comprising a mixture intended for oral administration, the mixture comprising: an opioid being (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrexone, naltrindole, nalbuphine, buprenorphine, or a mixture thereof; an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, fl-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, terpineol, (+)-limonene, 13-myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, polyethylene glycol (PEG) 400, PEG 2000, PEG 4000, Tween0 20, Tween0 60, Tween0 80, BRIJ 58, BRIJ 76, Pluronic0 F68, PluronicCD F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
These features and advantages of the present invention will be fully understood and appreciated from the following detailed description of the accompanying figures.
11 a BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts the temporal effect of capillarisin on the concentration of nalbuphine in blood, after the SD rats were orally treated with nalbuphine.
Figure 2 depicts the temporal effect of capillarisin on the concentration of nalbuphine in blood, after the SD rats were intravenously injected with nalbuphine.
Figure 3 compares the temporal effect of the concentration of nalbuphine in blood of SD rats between the samples and the controls. The control animals were treated with nalbuphine orally as well as intravenously while the sample animals were treated with nalbuphine and capillarisin.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In the first dimension, this invention provides a UGT2B inhibitor that is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, $ -naphthoflavone, a -naphthoflavone, hesperetinõ terpineol, (+)-limonene, 16 -myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a combination thereof.
In a good example of this invention, the UGT2B inhibitor is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, 13' -naphthoflavone, a -naphthoflavone, hesperetinõ terpineol, (+)-limonene, 13 -myrcene, swertiamarin and eriodictyol; or a combination of them. In a better example, the UGT2B
inhibitor contains capillarisin.
It was confirmed that UGT2B inhibitor of this invention can increase the bio-availability of a drug. The applicability of UGT2B inhibitor in the preparation of pharmaceutical compositions, especially the morphine analgesics, is also predicted in this invention.
Therefore, this invention provides a pharmaceutical composition which contains:
(a) a pharmacologically active ingredient of aforementioned UGT2B inhibitor, and (b) a pharmaceutically acceptable inert ingredient.
In the second dimension, this invention provides an UGT2B enhancer that is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, uteolin-7-glucoside, egosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, and trans-cinnamaldehyde.
In a good example of this invention, the UGT2B enhancer is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin and eriodictyol. A
better example of UGT2B enhancer contains nordihydroguaiaretic acid.
It was confirmed that the UGT2B enhancer of this invention can increase the clearance rate of a drug. The applicability of the UGT2B enhancer in the preparation of pharmaceutical compositions is also predicted in this invention.
Therefore, this invention provides a pharmaceutical composition which contains:
(a) a pharmacologically active ingredient of aforementioned UGT2B enhancer, and (b) a pharmaceutically acceptable inert ingredient.
In the pharmaceutical composition of this invention, the UGT2B enhancer is used along with a pharmaceutically effective amount of liver disease drugs.
The liver diseases include, but not limited to, viral hepatitis, chronic hepatitis, alcoholic liver cirrhosis, compensated cirrhosis, and hepatic failure.
The UGT2B inhibitor or enhancer used in this invention is easily obtainable to persons familiar with the technology. It can be chemically synthesized in the laboratory, purchased from chemical company, or purified from pertinent natural sources. The UGT2B inhibitor or enhancer used in the following experimental examples are purchased from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indofine Chemical Co., Inc. (Somerville, New Jersey).
In this invention, the term "pharmacologically active ingredient" refers to a pharmaceutical composition that can either inhibit or enhance the UGT2B
activity when a proper quantity was used in therapeutic purposes. The proper quantity of this active ingredient varies by type of disease, patient's weight, age, health condition, and the way the drug was delivered. It should be determined by technically qualified persons.
In this invention, the term "pharmaceutically acceptable" means that the salt component of an UGT2B inhibitor or enhancer must be compatible with other ingredients of the pharmaceutical composition, and will not hamper the application of this composition onto an individual.
The pharmaceutical composition of this invention can be used exclusively on an individual or in combination with morphine-like analgesic agents.
In a good example of this invention, the morphine-like analgesic agents include: (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, dihydromorphine, naltrexone, naltrindole, nalbuphine, and buprenorphine. In a better example, the morphine-like analgesic is nalbuphine.
The pharmaceutical composition of this invention can be manufactured as an intravenously- or orally-administered substance.
The pharmaceutical composition of this invention can be manufactured in a form for intravenous administration with the addition of sterile water or non-water solution, dispersion, suspension or emulsion, and sterile powder that can be reconstituted to sterile solution for injection. Examples of suitable water or non-water inert ingredients, diluents, solvents, or carriers include: water, alcohol, propylene glycol, polyethylene glycol, glycerol, or other similar compounds, and organic ester such as ethyl oleate.
It is better that the pharmaceutical composition of this invention be manufactured in a form that can be administered orally. The oral forms include solid substances (e.g., capsule, tablet, powder, and granule) and liquid substance (e.g., emulsion, solution, dispersion, suspension).
In addition, the pharmaceutical composition of this invention and other drugs can be presented in different forms. For example, it can be delivered as a tablet, by injection, or as an oral syrup. Furthermore, it is noteworthy that the pharmaceutical composition of this invention can be administered with other drugs at the same time or sequentially. For instance, as a tablet, it can be concentrated in a single tablet or spread to several tablets and can be given simultaneously or sequentially. All combinations, delivery methods and sequences can be flexibly administered by persons who are familiar with these techniques.
The dose and frequency in delivering the pharmaceutical composition of this invention varies according to: the severity of the illness to be treated, route of delivery, and the patient's weight, age, physical condition and the response.
In general, the dosage of the pharmaceutical composition of this invention is estimated to fall in the range of 0.01 mg/Kg weight to 20 mg/Kg, as a single dose or several doses, and can be delivered through a non-gastroenterological or oral route.
A detailed description of better examples The following experiments further describe the invention in detail. Please be advised that these experiments are examples. They are not the limitations of this invention's applications.
Experiment 1. in vitro experiment of UGT2B inhibitor Material and method:
1. The preparation of UGT2B inhibitor In the following experiment, 27 different kinds of CHEs and 10 different excipients were used as UGT2B inhibitor in this invention. These CHEs are pure compounds available commercially, and were purchased from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indofine Chemical Co., Inc.
(Somerville, New Jersey). Their category, name, source and chemical formula are listed in Table 1. These UGT2B inhibitors are dissolved in alcohol at the concentration of 1, 10, 100pM for the following experiment.
Besides, these excipients are commercially available pure compounds, they are PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127. These excipients are dissolved in water and make up to 0.5%, 5%, 50%(wt%, w/v) for the following experiment.(Note: BRIJ is a registered trademark of ICI Americas, Inc.;
Pluronic is a registered trademark of BASF Corporation.) Table 1. The category, name, source and chemical formula of UGT2B inhibitors Source Chemical formula and molecular Category Name (Scientific name) weight OH
Flavonoid Apigenin Chamomillae flos MW: 270.24 OH ¨
Isovitexin Swertiae herba HO 0 Glc0 MW : 432.38 OH
OMe Isorhamnetin Sennae folium OH
MW : 316.27 HO io 0 0 Aurantii fructus Umbelliferone immaturus (7-Hydroxycoumarin) MW :162.14 Source Chemical formula and molecular Category Name (Scientific name) weight =H
0 OMe RutO 0 0 _ 1 Diosmin MW : 608.55 0 OMe OH
Hesperetin Citri reticulatae HO 0 MW : 302.28 Glucuronic acid-0 is 0 40 I
baicalin Scutellariae radix HO
MW : 446.35 =H
=H
Puerarin Puerariae radix 40 I
. SOH
MW : 416.38 I
Artemisiae Capillarisin Me0 OH
capillaris herba OH 0 MW : 316.27 SI I
Genistein Puerariae radix OH
MW : 270.24 a - 0 1 Naphthoflavone _ o MW : 272.3 /3- 0 0 , _ Naphthoflavone MW : 272.3 Source Chemical formula and molecular Category Name (Scientific name) weight Cinnamami HO 0 OH
Eriodictyol cortex MW : 288.25 ,---.....
3-Phenylpropyl Cinnamami H3C 0 Acetate cortex MW :178.23 4, H. ,C, 40 C=C, H
Trans- Cinnamami Cinnamaldehyde cortex H
MW :132.16 cH2 Amome I
-,,, CH2 3-Myrcene cardamomi I
fructus 113C-CH, MW :136.23 essential oil el Cinae Terpineol flos(Santonica) OH
MW :154.25 Cardamomi el (+)-Limonene fructus H3C CH, MW :136.23 Ethyl Myristate Myristicae semen Cinae ICH3 o Cineole flos(Santonica) MW :154.25 Source Chemical formula and molecular Category Name (Scientific name) weight 0 _Io_cHa Tennins Paeoniflorin Paeoniae radix HOCH, 0 OH
HO HO
OH
MW: 480.47 OO
Swertiamarin Swertiae herba W=o-beta-D-glucose OH
MW : 374.34 chalcon Isoliquritigenin Astragali radix MW 256.25 COOH
CO
OH awl*
Glycyrrhizae Saponin Glycyrrhizin radix MW: 822.94 H,C
õleo COOH
Ursolic Acid Zizyphi fructus HO
NC CH, MW : 456.70 COOH
Protocatechuic Cinnamami acid cortex OH
OH
MW :154.12 COOH
Gallic Acid HO OH
OH
MW 170.12 Lauryl Alcohol MW :186.33 2. The preparation of liver microsome The Sprague-Dawley male rats, weighted 300-400 g are used as model animals in these experiments. The microsome is prepared as follows:
i. Sacrifice a rat after 12-16 hours fasting, take its liver; wipe dry the liver and weigh it.
ii. Add 300% (by volume) of cold 0.3M sucrose soluation, and homogenize the liver.
iii. Centrifuge the homogenized liver suspension at 9000 x g speed (KS-800, Kubota, made in Japan) for 10 min at 4 C. Collect the supernatant.
iv. Centrifuge the supernatant at 105,000xg speed (L8-60M, Beckman, made in USA) for 60 min at 4 C.
v. Remove the supernatant, add 0.3M sucrose (of the same volume) and repeat the homogenization. The homogenized liver suspension is the microsome.
Store the microsome at -70 C.
Thaw the microsome before use. Add 5p1/m1 BRIJO35 (Fisher et al. 2000, Drug Metabolism & Disposition. 28(5):560-6) into microsome by a ratio of microsome : BRIJS35 = 8 : 1 (v/v).
[noteBRIJO 35 SOLUTION 30% WN , BRIJ is a registered trademark of ICI Americas, Inc.]
3. Measure the protein amount in microsome The protein amount is determined as follows:
i. Take 0.1 ml microsome and dilute to 5m1 0.85 % NaC1 (50-fold dilution, v/v).
Take 0.2 ml of the diluted microsome and place it in a capped test tube (triple experiments). Separately, replacing microsome with 0.2 ml NaCl as the control.
ii. Add 2.2 ml Biuret regent (SIGMA, 690-A) into each test tube, mix well and store at room temperature for 10 min.
iii. Add 0.1 ml folin regent (SIGMA, 690-A), mix immediately, and store at room temperature for 30 min. Measure the absorbance at 550 nm wave length within the 30 min. Measure the concentration of protein in microsome based on the standard curve generated by various bovine albumin concentration and absorbance.
4. The measurement of the inhibition of UGT2B activity in vitro i. (A)solution: 17p1 1M Tris-HC1 buffer, 17p1 50mM MgCl2, 40p1 microsome and 10p1 150mM UDPGA solution.
(B)solution: mix 20mM nalbuphine solution with the inhibitor to be tested at the 1 : 1 ratio.
ii. Mix solution (A) and 17p1 solution (B) thoroughly, place in a 37 C water bath and shake at 125 rpm for 60 min.
iii. Add lml ACN to interrupt the reaction.
iv. Centrifuge at 130,000 xg speed at 4 C for 5 min, and v. Take 150 Ill supernatant and analyze the concentration of nalbuphine in a high performance liquid chromatography (HPLC).
5. The measurement of nalbuphine concentration (1) Condition of HPLC
The mobile phase consists of 15% sodium acetate (5 mM/L, pH 3) and 85%
ACN with a 1.0 ml/min flow rate. Set the spectrophotometer's (RF-551, Shimadzu, Kyoto, made in Japan) excitation wave length at 210 nm and emission wave length at 345 nm. Set the Ultra-violet detector's (SPD-10A, Shimadzu, Kyoto, made in Japan) wave length to 210 nm.
(2) Prepare the standard solution Prepare nalbuphine solution at 0.5, 1, 2.5, 5, 10, 15, 18, 20 mM
concentrations. Resolve the standard solution in water, but dilute the solution with alcohol if it contains inhibitor.
Use the same protocol as described in step 4 (The measurement of the inhibition of UGT2B activity in vitro), except that the de-ionized water, instead of the "150mM UDPGA solution" be used in the (A) solution.
After HPLC analysis, obtain a corrected curve by plotting HPLC reading of nalbuphine wave heights against its relative concentration. Analyze the standard deviation (SD), coefficient of variance (%CV), and %error to examine the accuracy.
Results:
The result is displayed in Table 2. Capillarisin has the best inhibitory effect on the metabolism of nalbuphine in microsome. The inhibition rate could reach 111.077 ( 21.807)%. Other CHEs including isorhamnetin,I3-naphthoflavone,a-naphthoflavone, hesperetin, terpineol, (+)-limonene, 13 -myrcene, swertiamarin, and eriodictyol also have at least 30%inhibition rate.
Table 2. The effect of the inhibitor on the metabolism of nalbuphine in liver microsome Name % Inhibition (Mean SD) 8.5 M 85 M 850 M
apigenin -26.668 13.062 53.998 15.763 -16.067 17.864 isovitexin 29.821 9.786 -5.528 9.096 -12.377 8.912 isorhamnetin 88.419 11.605 85.132 14.703 106.846 8.102 umbelliferone -14.707 5.810 4.596 8.236 -20.590 18.244 hesperetin 51.736 21.691 -59.096 18.879 -124.34 49.356 baicalin 36.298 9.403 46.253 22.923 44.262 2.879 puerarin 3.919 5.607 18.289 7.685
In sum, the development of a safe, effective and reversible UGT inhibitor will enable the oral administration of high "first-pass effect" drugs, and will minimize the side effect and the dosage of highly variable drugs. In addition, the toxicity of the carcinogenic compounds caused by UGT activities can also be reduced.
Developing a safe, efficient and reversible UGT enhancer is also a desirable goal of the pharmaceutical industry. It will help patients with low clearance rate in drug metabolism due to reduced liver functions to metabolize the drugs, and enhance the detoxification function of the liver.
SUMMARY OF THE INVENTION
First of all, this invention provides a UGT2B inhibitor that can increase the bio-availability of drugs. This inhibitor is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of:
capillarisin, isorhamnetin, 13-naphthoflavone, a-naphthoflavone, hesperetin, terpineol, (+)-limonene, P-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, terpineol, (+)-limonene, myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, TweenTm 20, TweenTm 60, TweenTm 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a combination thereof.
This invention also provides a pharmaceutical composition that includes the aforementioned UGT2B inhibitor as its active ingredient, and a pharmaceutically acceptable inert ingredient. The pharmaceutical composition in this invention can decrease the enzymatic activity of UGT2B, and thus increase the bio-availability of analgesics such as morphine.
Secondly, this invention provides an UGT2B enhancer that can improve the detoxification function of the liver. This enhancer is a compound with a free base or a pharmaceutically acceptable salt comprises of selected materials from the following: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, uteolin-7-glucoside, egosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, and trans-cinnamaldehyde.
This invention also provides a pharmaceutical composition that includes the aforementioned UGT2B enhancer as its active ingredient, and a pharmaceutically acceptable inert ingredient. The pharmaceutical composition in this invention can increase the enzymatic activity of UGT2B, and thus increase the clearance rate of a drug.
According to an aspect, the invention provides for a pharmaceutical composition comprising: an opioid; an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, fl-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, puerarin, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, polyethylene glycol (PEG) 400, PEG 2000, PEG 4000, Tween0 20, Tweent 60, Tween0 80, BRIJ 58, BRIJ 76, Pluronic0 F68, Pluronic0 F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
According to another aspect, the invention provides for a pharmaceutical composition comprising a mixture intended for oral administration, the mixture comprising: an opioid being (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrexone, naltrindole, nalbuphine, buprenorphine, or a mixture thereof; an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, fl-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, terpineol, (+)-limonene, 13-myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, polyethylene glycol (PEG) 400, PEG 2000, PEG 4000, Tween0 20, Tween0 60, Tween0 80, BRIJ 58, BRIJ 76, Pluronic0 F68, PluronicCD F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
These features and advantages of the present invention will be fully understood and appreciated from the following detailed description of the accompanying figures.
11 a BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts the temporal effect of capillarisin on the concentration of nalbuphine in blood, after the SD rats were orally treated with nalbuphine.
Figure 2 depicts the temporal effect of capillarisin on the concentration of nalbuphine in blood, after the SD rats were intravenously injected with nalbuphine.
Figure 3 compares the temporal effect of the concentration of nalbuphine in blood of SD rats between the samples and the controls. The control animals were treated with nalbuphine orally as well as intravenously while the sample animals were treated with nalbuphine and capillarisin.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In the first dimension, this invention provides a UGT2B inhibitor that is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, $ -naphthoflavone, a -naphthoflavone, hesperetinõ terpineol, (+)-limonene, 16 -myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a combination thereof.
In a good example of this invention, the UGT2B inhibitor is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, 13' -naphthoflavone, a -naphthoflavone, hesperetinõ terpineol, (+)-limonene, 13 -myrcene, swertiamarin and eriodictyol; or a combination of them. In a better example, the UGT2B
inhibitor contains capillarisin.
It was confirmed that UGT2B inhibitor of this invention can increase the bio-availability of a drug. The applicability of UGT2B inhibitor in the preparation of pharmaceutical compositions, especially the morphine analgesics, is also predicted in this invention.
Therefore, this invention provides a pharmaceutical composition which contains:
(a) a pharmacologically active ingredient of aforementioned UGT2B inhibitor, and (b) a pharmaceutically acceptable inert ingredient.
In the second dimension, this invention provides an UGT2B enhancer that is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)-epicatechin, uteolin-7-glucoside, egosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, and trans-cinnamaldehyde.
In a good example of this invention, the UGT2B enhancer is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin and eriodictyol. A
better example of UGT2B enhancer contains nordihydroguaiaretic acid.
It was confirmed that the UGT2B enhancer of this invention can increase the clearance rate of a drug. The applicability of the UGT2B enhancer in the preparation of pharmaceutical compositions is also predicted in this invention.
Therefore, this invention provides a pharmaceutical composition which contains:
(a) a pharmacologically active ingredient of aforementioned UGT2B enhancer, and (b) a pharmaceutically acceptable inert ingredient.
In the pharmaceutical composition of this invention, the UGT2B enhancer is used along with a pharmaceutically effective amount of liver disease drugs.
The liver diseases include, but not limited to, viral hepatitis, chronic hepatitis, alcoholic liver cirrhosis, compensated cirrhosis, and hepatic failure.
The UGT2B inhibitor or enhancer used in this invention is easily obtainable to persons familiar with the technology. It can be chemically synthesized in the laboratory, purchased from chemical company, or purified from pertinent natural sources. The UGT2B inhibitor or enhancer used in the following experimental examples are purchased from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indofine Chemical Co., Inc. (Somerville, New Jersey).
In this invention, the term "pharmacologically active ingredient" refers to a pharmaceutical composition that can either inhibit or enhance the UGT2B
activity when a proper quantity was used in therapeutic purposes. The proper quantity of this active ingredient varies by type of disease, patient's weight, age, health condition, and the way the drug was delivered. It should be determined by technically qualified persons.
In this invention, the term "pharmaceutically acceptable" means that the salt component of an UGT2B inhibitor or enhancer must be compatible with other ingredients of the pharmaceutical composition, and will not hamper the application of this composition onto an individual.
The pharmaceutical composition of this invention can be used exclusively on an individual or in combination with morphine-like analgesic agents.
In a good example of this invention, the morphine-like analgesic agents include: (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, dihydromorphine, naltrexone, naltrindole, nalbuphine, and buprenorphine. In a better example, the morphine-like analgesic is nalbuphine.
The pharmaceutical composition of this invention can be manufactured as an intravenously- or orally-administered substance.
The pharmaceutical composition of this invention can be manufactured in a form for intravenous administration with the addition of sterile water or non-water solution, dispersion, suspension or emulsion, and sterile powder that can be reconstituted to sterile solution for injection. Examples of suitable water or non-water inert ingredients, diluents, solvents, or carriers include: water, alcohol, propylene glycol, polyethylene glycol, glycerol, or other similar compounds, and organic ester such as ethyl oleate.
It is better that the pharmaceutical composition of this invention be manufactured in a form that can be administered orally. The oral forms include solid substances (e.g., capsule, tablet, powder, and granule) and liquid substance (e.g., emulsion, solution, dispersion, suspension).
In addition, the pharmaceutical composition of this invention and other drugs can be presented in different forms. For example, it can be delivered as a tablet, by injection, or as an oral syrup. Furthermore, it is noteworthy that the pharmaceutical composition of this invention can be administered with other drugs at the same time or sequentially. For instance, as a tablet, it can be concentrated in a single tablet or spread to several tablets and can be given simultaneously or sequentially. All combinations, delivery methods and sequences can be flexibly administered by persons who are familiar with these techniques.
The dose and frequency in delivering the pharmaceutical composition of this invention varies according to: the severity of the illness to be treated, route of delivery, and the patient's weight, age, physical condition and the response.
In general, the dosage of the pharmaceutical composition of this invention is estimated to fall in the range of 0.01 mg/Kg weight to 20 mg/Kg, as a single dose or several doses, and can be delivered through a non-gastroenterological or oral route.
A detailed description of better examples The following experiments further describe the invention in detail. Please be advised that these experiments are examples. They are not the limitations of this invention's applications.
Experiment 1. in vitro experiment of UGT2B inhibitor Material and method:
1. The preparation of UGT2B inhibitor In the following experiment, 27 different kinds of CHEs and 10 different excipients were used as UGT2B inhibitor in this invention. These CHEs are pure compounds available commercially, and were purchased from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indofine Chemical Co., Inc.
(Somerville, New Jersey). Their category, name, source and chemical formula are listed in Table 1. These UGT2B inhibitors are dissolved in alcohol at the concentration of 1, 10, 100pM for the following experiment.
Besides, these excipients are commercially available pure compounds, they are PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127. These excipients are dissolved in water and make up to 0.5%, 5%, 50%(wt%, w/v) for the following experiment.(Note: BRIJ is a registered trademark of ICI Americas, Inc.;
Pluronic is a registered trademark of BASF Corporation.) Table 1. The category, name, source and chemical formula of UGT2B inhibitors Source Chemical formula and molecular Category Name (Scientific name) weight OH
Flavonoid Apigenin Chamomillae flos MW: 270.24 OH ¨
Isovitexin Swertiae herba HO 0 Glc0 MW : 432.38 OH
OMe Isorhamnetin Sennae folium OH
MW : 316.27 HO io 0 0 Aurantii fructus Umbelliferone immaturus (7-Hydroxycoumarin) MW :162.14 Source Chemical formula and molecular Category Name (Scientific name) weight =H
0 OMe RutO 0 0 _ 1 Diosmin MW : 608.55 0 OMe OH
Hesperetin Citri reticulatae HO 0 MW : 302.28 Glucuronic acid-0 is 0 40 I
baicalin Scutellariae radix HO
MW : 446.35 =H
=H
Puerarin Puerariae radix 40 I
. SOH
MW : 416.38 I
Artemisiae Capillarisin Me0 OH
capillaris herba OH 0 MW : 316.27 SI I
Genistein Puerariae radix OH
MW : 270.24 a - 0 1 Naphthoflavone _ o MW : 272.3 /3- 0 0 , _ Naphthoflavone MW : 272.3 Source Chemical formula and molecular Category Name (Scientific name) weight Cinnamami HO 0 OH
Eriodictyol cortex MW : 288.25 ,---.....
3-Phenylpropyl Cinnamami H3C 0 Acetate cortex MW :178.23 4, H. ,C, 40 C=C, H
Trans- Cinnamami Cinnamaldehyde cortex H
MW :132.16 cH2 Amome I
-,,, CH2 3-Myrcene cardamomi I
fructus 113C-CH, MW :136.23 essential oil el Cinae Terpineol flos(Santonica) OH
MW :154.25 Cardamomi el (+)-Limonene fructus H3C CH, MW :136.23 Ethyl Myristate Myristicae semen Cinae ICH3 o Cineole flos(Santonica) MW :154.25 Source Chemical formula and molecular Category Name (Scientific name) weight 0 _Io_cHa Tennins Paeoniflorin Paeoniae radix HOCH, 0 OH
HO HO
OH
MW: 480.47 OO
Swertiamarin Swertiae herba W=o-beta-D-glucose OH
MW : 374.34 chalcon Isoliquritigenin Astragali radix MW 256.25 COOH
CO
OH awl*
Glycyrrhizae Saponin Glycyrrhizin radix MW: 822.94 H,C
õleo COOH
Ursolic Acid Zizyphi fructus HO
NC CH, MW : 456.70 COOH
Protocatechuic Cinnamami acid cortex OH
OH
MW :154.12 COOH
Gallic Acid HO OH
OH
MW 170.12 Lauryl Alcohol MW :186.33 2. The preparation of liver microsome The Sprague-Dawley male rats, weighted 300-400 g are used as model animals in these experiments. The microsome is prepared as follows:
i. Sacrifice a rat after 12-16 hours fasting, take its liver; wipe dry the liver and weigh it.
ii. Add 300% (by volume) of cold 0.3M sucrose soluation, and homogenize the liver.
iii. Centrifuge the homogenized liver suspension at 9000 x g speed (KS-800, Kubota, made in Japan) for 10 min at 4 C. Collect the supernatant.
iv. Centrifuge the supernatant at 105,000xg speed (L8-60M, Beckman, made in USA) for 60 min at 4 C.
v. Remove the supernatant, add 0.3M sucrose (of the same volume) and repeat the homogenization. The homogenized liver suspension is the microsome.
Store the microsome at -70 C.
Thaw the microsome before use. Add 5p1/m1 BRIJO35 (Fisher et al. 2000, Drug Metabolism & Disposition. 28(5):560-6) into microsome by a ratio of microsome : BRIJS35 = 8 : 1 (v/v).
[noteBRIJO 35 SOLUTION 30% WN , BRIJ is a registered trademark of ICI Americas, Inc.]
3. Measure the protein amount in microsome The protein amount is determined as follows:
i. Take 0.1 ml microsome and dilute to 5m1 0.85 % NaC1 (50-fold dilution, v/v).
Take 0.2 ml of the diluted microsome and place it in a capped test tube (triple experiments). Separately, replacing microsome with 0.2 ml NaCl as the control.
ii. Add 2.2 ml Biuret regent (SIGMA, 690-A) into each test tube, mix well and store at room temperature for 10 min.
iii. Add 0.1 ml folin regent (SIGMA, 690-A), mix immediately, and store at room temperature for 30 min. Measure the absorbance at 550 nm wave length within the 30 min. Measure the concentration of protein in microsome based on the standard curve generated by various bovine albumin concentration and absorbance.
4. The measurement of the inhibition of UGT2B activity in vitro i. (A)solution: 17p1 1M Tris-HC1 buffer, 17p1 50mM MgCl2, 40p1 microsome and 10p1 150mM UDPGA solution.
(B)solution: mix 20mM nalbuphine solution with the inhibitor to be tested at the 1 : 1 ratio.
ii. Mix solution (A) and 17p1 solution (B) thoroughly, place in a 37 C water bath and shake at 125 rpm for 60 min.
iii. Add lml ACN to interrupt the reaction.
iv. Centrifuge at 130,000 xg speed at 4 C for 5 min, and v. Take 150 Ill supernatant and analyze the concentration of nalbuphine in a high performance liquid chromatography (HPLC).
5. The measurement of nalbuphine concentration (1) Condition of HPLC
The mobile phase consists of 15% sodium acetate (5 mM/L, pH 3) and 85%
ACN with a 1.0 ml/min flow rate. Set the spectrophotometer's (RF-551, Shimadzu, Kyoto, made in Japan) excitation wave length at 210 nm and emission wave length at 345 nm. Set the Ultra-violet detector's (SPD-10A, Shimadzu, Kyoto, made in Japan) wave length to 210 nm.
(2) Prepare the standard solution Prepare nalbuphine solution at 0.5, 1, 2.5, 5, 10, 15, 18, 20 mM
concentrations. Resolve the standard solution in water, but dilute the solution with alcohol if it contains inhibitor.
Use the same protocol as described in step 4 (The measurement of the inhibition of UGT2B activity in vitro), except that the de-ionized water, instead of the "150mM UDPGA solution" be used in the (A) solution.
After HPLC analysis, obtain a corrected curve by plotting HPLC reading of nalbuphine wave heights against its relative concentration. Analyze the standard deviation (SD), coefficient of variance (%CV), and %error to examine the accuracy.
Results:
The result is displayed in Table 2. Capillarisin has the best inhibitory effect on the metabolism of nalbuphine in microsome. The inhibition rate could reach 111.077 ( 21.807)%. Other CHEs including isorhamnetin,I3-naphthoflavone,a-naphthoflavone, hesperetin, terpineol, (+)-limonene, 13 -myrcene, swertiamarin, and eriodictyol also have at least 30%inhibition rate.
Table 2. The effect of the inhibitor on the metabolism of nalbuphine in liver microsome Name % Inhibition (Mean SD) 8.5 M 85 M 850 M
apigenin -26.668 13.062 53.998 15.763 -16.067 17.864 isovitexin 29.821 9.786 -5.528 9.096 -12.377 8.912 isorhamnetin 88.419 11.605 85.132 14.703 106.846 8.102 umbelliferone -14.707 5.810 4.596 8.236 -20.590 18.244 hesperetin 51.736 21.691 -59.096 18.879 -124.34 49.356 baicalin 36.298 9.403 46.253 22.923 44.262 2.879 puerarin 3.919 5.607 18.289 7.685
10.103 5.841 capillarisin 111.077 21.807 105.410 21.808 105.257 19.306 genistein 15.630 6.046 5.733 6.406 -9.200 5.182 a- naphthoflavone 72.33 2.811 97.79 4.370 90.81 7.175 13.- naphthoflavone 95.82 5.461 86.02 16.487 99.72 15.877 eriodictyol -1.061 3.714 -17.133 2.297 14.114 2.878 3-phenylpropyl acetate -26.288 27.337 17.280 5.837 2.390 22.463 trans-cinnamaldehyde -6.973 3.782 -3.099 9.457 18.284 10.350 13 -myrcene 16.812 1.716 35.290 0.220 34.883 7.296 terpineol 40.558 6.511 62.367 2.582 58.164 4.241 (+)-limonene 18.284 0.793 45.284 7.844 44.238 2.284 ethyl myristate -27.845 14.692 -12.134 5.706 6.326 1.484 cineole -8.413 18.562 -12.107 6.679 58.890 8.558 paeoniflorin 12.093 8.544 17.797 9.248 -2.966 9.529 swertiamarin 28.239 2.248 27.930 4.129 -2.499 6.899 isoliquritigenin -2.482 5.506 17.592 4.565 18.637 16.623 glycyrrhizin 9.926 6.659 -20.298 3.674 -5.653 6.620 ursolic acid 34.171 18.576 17.267 14.316 6.482 18.840 protocatechuic acid -20.210 5.957 -4.563 3.372 9.844 1.872 gallic acid 15.842 4.418 8.051 3.024 12.223 4.080 lauryl alcohol 14.422 3.370 19.496 3.464 6.232 6.752 Besides, figure 3 and 4 depict the result about the excipients in the experiment above. PEG 4000 has the best inhibitory effect on the metabolism of nalbuphine in microsome, the inhibitory rate reaches 108.222 ( 3.356) %; the best inhibitory rate of the other excipients reach 60% at least.
Table 3 The effect of the excipient on the metabolism of nalbuphine in liver microsome-1 Name % Inhibition (Mean SD) Concentration of 0.0425% 0.425% 4.25%
excipients ( wt%, w/v ) PEG 400 102.137 6.156 97.030 12.875 93.359 10.893 PEG 2000 32.615 5.192 86.635 7.948 97.011 4.588 PEG 4000 71.410 3.109 108.222 3.356 107.329 6.242 Tween 20 83.734 6.465 99.863 8.487 93.926 7.862 Tween 60 78.475 4.915 30.917 7.429 27.327 9.644 Tween 80 91.163 5.861 92.387 6.302 99.651 3.344 Table4 The effect of the excipient on the metabolism of nalbuphine in liver microsome-2 Name % Inhibition (Mean SD) Concentration of 0.02125% 0.2125% 2.125%
excipient ( wt%, w/v ) BRIJ 58 78.117 6.634 41.592 5.606 -33.648
Table 3 The effect of the excipient on the metabolism of nalbuphine in liver microsome-1 Name % Inhibition (Mean SD) Concentration of 0.0425% 0.425% 4.25%
excipients ( wt%, w/v ) PEG 400 102.137 6.156 97.030 12.875 93.359 10.893 PEG 2000 32.615 5.192 86.635 7.948 97.011 4.588 PEG 4000 71.410 3.109 108.222 3.356 107.329 6.242 Tween 20 83.734 6.465 99.863 8.487 93.926 7.862 Tween 60 78.475 4.915 30.917 7.429 27.327 9.644 Tween 80 91.163 5.861 92.387 6.302 99.651 3.344 Table4 The effect of the excipient on the metabolism of nalbuphine in liver microsome-2 Name % Inhibition (Mean SD) Concentration of 0.02125% 0.2125% 2.125%
excipient ( wt%, w/v ) BRIJ 58 78.117 6.634 41.592 5.606 -33.648
11.873 BRIJ 76 40.488 2.327 29.959 2.572 60.439 7.751 Pluronic F68 97.431 5.764 98.925 4.475 65.768 2.371 Pluronic F127 14.499 28.385 70.247 36.296 83.845 16.451 Experiment 2. in virto experiment of UGT2B enhancer This experiment uses the same protocol described in Experiment 1, except by testing the 40 CHEs listed in Table 5 as the UGT2B enhancer. Those CHEs are commercially available pure compounds, acquired from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indole Chemical Co. Inc (Somerville, New Jersey). Their categories, names, sources, and chemical compositions are described in Table 5.
Table 5. Category, name, source, and chemical composition of the UGT2B
enhancers.
Source Chemical formula and molecular Category Name (scientific name) weight Me0 o Artemisiae Flavonoid Genkwanin go I
cpillaris herba MW : 284.27 Apigenin Chamomillae flos HO 0 MW : 270.24 = H
0 Luteolin Digitals folium HO 0I
MW : 286.24 = H
Glc0 0 0 Lute0lin_7 -Glucoside Digitals folium I
MW: 448.39 Source Chemical formula and molecular Category Name (scientific name) weight OH
SOH
I
Homoorientin Swertiae herba Glc0 MW: 448.39 Isovitexin Swertiae herba Go() MW : 432.38 OMe SOH
Neohesperidin Aurantii fructus immaturus OH 0 X: Neohesperidoside MW : 610.57 I
Formononetin Astragali radix o el OMe MW : 268.27 I
KaeMpfer01 Sennae folium HO 0 OH
MW : 286.24 sH
Hydrangeae HO o Isoquercitrin dukis folium 0 1 0-beta-D-glucose MW: 464.38 6-Gingerol Zingiberis HO lel CH3 OMe MW : 294.38 Source Chemical formula and molecular Category Name (scientific name) weight HO 0 ,,, 1.1101-1, Liquiritin Glycyrrizae radix KOHY
OH
OH
MW
OH
HO o Aurantii fructus naringenin immaturus MW 272.26 Aurantii fructus Umbelliferone immaturus (7-Hydroxycoumarin) MW 162.14 OH
Rutin Sophorae flos HO 0 ORut MW 664.58 OMe HAcE7 0,3 ¨jor;
Aurantii fructus 3 H
"IIP OH
Hesperidin OH OH __ immaturus OH
MW 610.57 =H
OMe RutO 0 Diosmin I
MW 608.55 OMe OH
Hesperetin Citri reticulatae HO 0 MW 302.28 Source Chemical formula and molecular Category Name (scientific name) weight OMe I
Wogonin Scutellariae radix HO 0 MW : 284.27 Baicalein Scutellariae radix SI
HO
MW: 270.24 I
Daidzein Puerariae radix OH
o MW : 254.24 tH.0:1,1 I
Daidzin Puerariae radix OH
0 I.
OH
OH
MW: 416.38 io I
Quercitrin Viscum coloratum HO 0 OH
ORha MW: 448.38 I* OH
I
Quercetin Viscum coloratum HO 0 OH
OH
MW: 302.2 OH
Nordihydroguaiar HO
-etic acid CH, HO
MW : 302.36 I
Genistein Puerariae radix OH
MW : 270.24 Source Chemical formula and molecular Category Name (scientific name) weight OMe Neohespendose 0 ial 0 1.1 Aurantii fructus Poncirin 1W
immaturus MW : 594.37 ,OH
XO ao 0 Narigin Aurantii fructus immaturus OH 0 X:Rhamnoglucoside MW : 580.54 OH
Cinnamami HO 0 Eriodictyol cortex MW : 288.25 3-Phenylpropyl Cinnamami H3C4:3 Acetate cortex MW :178.23 H. ,C, 10 C=C H
Trans- Cinnamami \H
Cinnamaldehyde cortex essential oil MW :132.16 Ethyl Myristate Myristicae semen Cinae Cineole a-13>
flos(Santonica) C
H3c CH3 MW :154.25 itTennins (+)-Epicatechin Gambir HO 0 OH
OH
OH
MW : 290.27 Source Chemical formula and molecular Category Name (scientific name) weight OH
OH
(+)-Catechin Paeoniae radix OH
OH
MW 290.27 OH
OH
(-)-Epicatechin Gambir OH
OH
MW 290.27 cH, CH, Sterol Ergosterol Holen(poria) CH, OM
HO
MW 396.65 H,0,s COOH
CH, goo Saponin Glycyrrhizin Glycyrrhizae OHOH
radix 6T4 H,C CH, OH
MW : 822.94 1-13c C H3 Triterpenoid Oleanolic Acid Zizyphi fructus HO
MW: 456.70 COOH
PrOtOCateChUiC Cinnamami acid cortex OH
OH
MW 154.12 Trans-Cinnamic c=c'cOH
Acid ===
Source Chemical formula and molecular Category Name (scientific name) weight MW :148.16 Result:
The results are summarized in Table 6. The nordihydroguaiaretic acid exhibited the best enhancement effect on the metabolism of nalbuphine in liver microsome. It could reach a -188.09( 16.566)%rate of inhibition. The other CHEs including wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol could have at least 30% enhancement rate.
Table 6. The effect of the enhancers on the metabolism of nalbuphine in liver microsome Enhancer % Inhibition (Mean SD) 8.5 1µ4 85 M 850 tiM
genkwanin -26.999 4.509 -77.684 20.682 -43.231 18.793 apigenin -26.668 13.062 53.998 15.763 -16.067 17.864 luteolin -25.508 26.594 -28.324 15.205 -17.558 12.135 luteolin-7-glucoside -45.053 3.583 -36.109 9.203 -47.869 26.599 homoorientin -128.53 27.613 -127.21 28.005 -133.17 26.968 isovitexin 29.821 9.786 -5.528 9.096 -12.377 8.912 neohesperidin -66.586 9.614 -113.63 8.986 -113.46 16.721 formononetin -86.463 3.490 -31.471 4.775 -24.680 4.417 kaempferol -19.545 14.198 -76.028 27.291 -71.058 4.509 isoquercitrin -8.089 2.404 -19.119 21.887 -71.696 20.468 6-gingerol -14.156 4.469 -13.378 3.967 -12.341 1.579 liquiritin -9.382 1.803 -17.704 8.510 -29.167 2.737 6-gingerol -62.872 41.065 -48.35 13.179 -22.61 14.532 umbelliferone -14.707 5.810 4.596 8.236 -20.590 18.244 rutin -19.854 19.742 -29.414 29.485 -33.458 13.373 hesperidin 2.163 2.725 -31.997 10.339 -42.02 4.245 hesperetin 51.736 21.691 -59.096 18.879 -124.34 49.356 wogonin -128.63 8.286 -153.23 6.491 -135.55 2.879 -145.76 8.474 baicalein -99.628 12.832 -125.44 8.620 (212.5 1.1,M) -138.40 2.307 daidzein -127.64 20.806 -138.29 4.617 (4251.1M) daidzin -29.524 21.990 -41.466 16.977 -61.04 21.066 quercitrin -81.27 15.027 -83.60 27.446 -55.57 12.151 quercetin -81.440 5.593 -142.98 18.532 -119.26 19.351 nordihydroguaiaretic -142.15 41.001 -165.04 22.961 -188.09 16.566 acid genistein 15.630 6.046 5.733 6.406 -9.200 5.182 poncirin -16.068 8.122 -8.448 8.261 -7.098 18.196 narigin -124.10 16.541 -80.70 4.927 -98.15 5.276 3-phenylpropyl acetate -26.288 27.337 17.280 5.837 2.390 22.463 trans-cinnamaldehyde -6.973 3.782 -3.099 9.457 18.284 10.350 ethyl myristate -27.845 14.692 -12.134 5.706 6.326 1.484 cineole -8.413 18.562 -12.107 6.679 58.890 8.558 (+)-epicatechin -32.553 1.578 -47.075 0.533 -8.118 1.256 (+)-catechin -68.387 7.344 -54.783 9.381 -65.261 47.038 (-)-epicatechin -28.68 17.634 -23.53 27.304 -48.35 39.354 ergosterol -12.501 28.884 -28.311 20.311 -34.561 19.877 glycyrrhizin 9.926 6.659 -20.298 3.674 -5.653 6.620 oleanolic acid -87.200 24.408 -135.54 15.185 -128.64 22.066 protocatechuic acid -20.210 5.957 -4.563 3.372 9.844 1.872 eriodictyol -1.061 3.714 -17.133 2.297 14.114 2.878 trans-cinnamic acid -153.03 24.865 -109.06 18.574 -134.74 3.90 Experiment 3. The effect of UGT2B inhibitors on the concentration of nalbuphine taken orally Material and methods:
1. Experimental animal Healthy male Sprague-Dawley rat, weight 500-600g, acquired from National Laboratory Animal Breeding and Research Center in Taiwan, are used.
After the acquisition, the animals are kept in a room with constant temperature (at 25 1 C), humidity and day light (12 hours per day) for one week. Before the experiment, the animals are fasted for 12-16 hours. The drugs are administered orally.
2. Preparation of UGT2B inhibitor and nalbuphine solution Standard solution of nalbuphine is dissolved in water, and all inhibitors are dissolved in alcohol.
3. Methods:
i. Anesthetize the rat with 3-5mg/100g body weight of pentobarbital intraperitoneally (I.P.). The rat will be anesthetized in about 20-30 min.
ii. Insert the PE-50 catheter tube into external jugular vein to sample the blood.
iii. Orally administered 6 rats with UGT2B inhibitor--capillarisin (4mg/Kg body weight) and nalbuphine solution (100mg/Kg body weight). Use another 6 rats as the control. They were given only nalbuphine solution (100 mg/Kg body weight). Take 0.3 mL blood sample at the 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8,
Table 5. Category, name, source, and chemical composition of the UGT2B
enhancers.
Source Chemical formula and molecular Category Name (scientific name) weight Me0 o Artemisiae Flavonoid Genkwanin go I
cpillaris herba MW : 284.27 Apigenin Chamomillae flos HO 0 MW : 270.24 = H
0 Luteolin Digitals folium HO 0I
MW : 286.24 = H
Glc0 0 0 Lute0lin_7 -Glucoside Digitals folium I
MW: 448.39 Source Chemical formula and molecular Category Name (scientific name) weight OH
SOH
I
Homoorientin Swertiae herba Glc0 MW: 448.39 Isovitexin Swertiae herba Go() MW : 432.38 OMe SOH
Neohesperidin Aurantii fructus immaturus OH 0 X: Neohesperidoside MW : 610.57 I
Formononetin Astragali radix o el OMe MW : 268.27 I
KaeMpfer01 Sennae folium HO 0 OH
MW : 286.24 sH
Hydrangeae HO o Isoquercitrin dukis folium 0 1 0-beta-D-glucose MW: 464.38 6-Gingerol Zingiberis HO lel CH3 OMe MW : 294.38 Source Chemical formula and molecular Category Name (scientific name) weight HO 0 ,,, 1.1101-1, Liquiritin Glycyrrizae radix KOHY
OH
OH
MW
OH
HO o Aurantii fructus naringenin immaturus MW 272.26 Aurantii fructus Umbelliferone immaturus (7-Hydroxycoumarin) MW 162.14 OH
Rutin Sophorae flos HO 0 ORut MW 664.58 OMe HAcE7 0,3 ¨jor;
Aurantii fructus 3 H
"IIP OH
Hesperidin OH OH __ immaturus OH
MW 610.57 =H
OMe RutO 0 Diosmin I
MW 608.55 OMe OH
Hesperetin Citri reticulatae HO 0 MW 302.28 Source Chemical formula and molecular Category Name (scientific name) weight OMe I
Wogonin Scutellariae radix HO 0 MW : 284.27 Baicalein Scutellariae radix SI
HO
MW: 270.24 I
Daidzein Puerariae radix OH
o MW : 254.24 tH.0:1,1 I
Daidzin Puerariae radix OH
0 I.
OH
OH
MW: 416.38 io I
Quercitrin Viscum coloratum HO 0 OH
ORha MW: 448.38 I* OH
I
Quercetin Viscum coloratum HO 0 OH
OH
MW: 302.2 OH
Nordihydroguaiar HO
-etic acid CH, HO
MW : 302.36 I
Genistein Puerariae radix OH
MW : 270.24 Source Chemical formula and molecular Category Name (scientific name) weight OMe Neohespendose 0 ial 0 1.1 Aurantii fructus Poncirin 1W
immaturus MW : 594.37 ,OH
XO ao 0 Narigin Aurantii fructus immaturus OH 0 X:Rhamnoglucoside MW : 580.54 OH
Cinnamami HO 0 Eriodictyol cortex MW : 288.25 3-Phenylpropyl Cinnamami H3C4:3 Acetate cortex MW :178.23 H. ,C, 10 C=C H
Trans- Cinnamami \H
Cinnamaldehyde cortex essential oil MW :132.16 Ethyl Myristate Myristicae semen Cinae Cineole a-13>
flos(Santonica) C
H3c CH3 MW :154.25 itTennins (+)-Epicatechin Gambir HO 0 OH
OH
OH
MW : 290.27 Source Chemical formula and molecular Category Name (scientific name) weight OH
OH
(+)-Catechin Paeoniae radix OH
OH
MW 290.27 OH
OH
(-)-Epicatechin Gambir OH
OH
MW 290.27 cH, CH, Sterol Ergosterol Holen(poria) CH, OM
HO
MW 396.65 H,0,s COOH
CH, goo Saponin Glycyrrhizin Glycyrrhizae OHOH
radix 6T4 H,C CH, OH
MW : 822.94 1-13c C H3 Triterpenoid Oleanolic Acid Zizyphi fructus HO
MW: 456.70 COOH
PrOtOCateChUiC Cinnamami acid cortex OH
OH
MW 154.12 Trans-Cinnamic c=c'cOH
Acid ===
Source Chemical formula and molecular Category Name (scientific name) weight MW :148.16 Result:
The results are summarized in Table 6. The nordihydroguaiaretic acid exhibited the best enhancement effect on the metabolism of nalbuphine in liver microsome. It could reach a -188.09( 16.566)%rate of inhibition. The other CHEs including wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol could have at least 30% enhancement rate.
Table 6. The effect of the enhancers on the metabolism of nalbuphine in liver microsome Enhancer % Inhibition (Mean SD) 8.5 1µ4 85 M 850 tiM
genkwanin -26.999 4.509 -77.684 20.682 -43.231 18.793 apigenin -26.668 13.062 53.998 15.763 -16.067 17.864 luteolin -25.508 26.594 -28.324 15.205 -17.558 12.135 luteolin-7-glucoside -45.053 3.583 -36.109 9.203 -47.869 26.599 homoorientin -128.53 27.613 -127.21 28.005 -133.17 26.968 isovitexin 29.821 9.786 -5.528 9.096 -12.377 8.912 neohesperidin -66.586 9.614 -113.63 8.986 -113.46 16.721 formononetin -86.463 3.490 -31.471 4.775 -24.680 4.417 kaempferol -19.545 14.198 -76.028 27.291 -71.058 4.509 isoquercitrin -8.089 2.404 -19.119 21.887 -71.696 20.468 6-gingerol -14.156 4.469 -13.378 3.967 -12.341 1.579 liquiritin -9.382 1.803 -17.704 8.510 -29.167 2.737 6-gingerol -62.872 41.065 -48.35 13.179 -22.61 14.532 umbelliferone -14.707 5.810 4.596 8.236 -20.590 18.244 rutin -19.854 19.742 -29.414 29.485 -33.458 13.373 hesperidin 2.163 2.725 -31.997 10.339 -42.02 4.245 hesperetin 51.736 21.691 -59.096 18.879 -124.34 49.356 wogonin -128.63 8.286 -153.23 6.491 -135.55 2.879 -145.76 8.474 baicalein -99.628 12.832 -125.44 8.620 (212.5 1.1,M) -138.40 2.307 daidzein -127.64 20.806 -138.29 4.617 (4251.1M) daidzin -29.524 21.990 -41.466 16.977 -61.04 21.066 quercitrin -81.27 15.027 -83.60 27.446 -55.57 12.151 quercetin -81.440 5.593 -142.98 18.532 -119.26 19.351 nordihydroguaiaretic -142.15 41.001 -165.04 22.961 -188.09 16.566 acid genistein 15.630 6.046 5.733 6.406 -9.200 5.182 poncirin -16.068 8.122 -8.448 8.261 -7.098 18.196 narigin -124.10 16.541 -80.70 4.927 -98.15 5.276 3-phenylpropyl acetate -26.288 27.337 17.280 5.837 2.390 22.463 trans-cinnamaldehyde -6.973 3.782 -3.099 9.457 18.284 10.350 ethyl myristate -27.845 14.692 -12.134 5.706 6.326 1.484 cineole -8.413 18.562 -12.107 6.679 58.890 8.558 (+)-epicatechin -32.553 1.578 -47.075 0.533 -8.118 1.256 (+)-catechin -68.387 7.344 -54.783 9.381 -65.261 47.038 (-)-epicatechin -28.68 17.634 -23.53 27.304 -48.35 39.354 ergosterol -12.501 28.884 -28.311 20.311 -34.561 19.877 glycyrrhizin 9.926 6.659 -20.298 3.674 -5.653 6.620 oleanolic acid -87.200 24.408 -135.54 15.185 -128.64 22.066 protocatechuic acid -20.210 5.957 -4.563 3.372 9.844 1.872 eriodictyol -1.061 3.714 -17.133 2.297 14.114 2.878 trans-cinnamic acid -153.03 24.865 -109.06 18.574 -134.74 3.90 Experiment 3. The effect of UGT2B inhibitors on the concentration of nalbuphine taken orally Material and methods:
1. Experimental animal Healthy male Sprague-Dawley rat, weight 500-600g, acquired from National Laboratory Animal Breeding and Research Center in Taiwan, are used.
After the acquisition, the animals are kept in a room with constant temperature (at 25 1 C), humidity and day light (12 hours per day) for one week. Before the experiment, the animals are fasted for 12-16 hours. The drugs are administered orally.
2. Preparation of UGT2B inhibitor and nalbuphine solution Standard solution of nalbuphine is dissolved in water, and all inhibitors are dissolved in alcohol.
3. Methods:
i. Anesthetize the rat with 3-5mg/100g body weight of pentobarbital intraperitoneally (I.P.). The rat will be anesthetized in about 20-30 min.
ii. Insert the PE-50 catheter tube into external jugular vein to sample the blood.
iii. Orally administered 6 rats with UGT2B inhibitor--capillarisin (4mg/Kg body weight) and nalbuphine solution (100mg/Kg body weight). Use another 6 rats as the control. They were given only nalbuphine solution (100 mg/Kg body weight). Take 0.3 mL blood sample at the 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8,
12 and 24 hours after treated with these drugs, centrifuge at 10000 rpm, and take 0.1 mL serum for an analysis of the concentration of nalbuphine.
4. Measurement of the concentration of nalbuphine (1) Sample preparation Place 0.1 mL serum in a 10 mL test tube and quickly transfer it to an ice bath. Add 50 pL internal standard (buprenorphine 5 pg/mL) and 05 mL sodium carbonate buffer (0.5 mole/L, pH=9.25) and mixed well. Extract the serum with mL n-hexane and isoamyl alcohol mixture (9:1 (v/v)), and shake for 20 min.
Centrifuge at 1,080xg speed at 4 C for 15 min, then place it in a -80 C
freezer until the water layer froze. Transfer the organic solvent layer into another clean test tube, lyophylized until dried. Add 100pL ACN to dissolve the dried material, auto-pipette 50pL and applied to HPLC for analyzing the concentration.
(2) Condition for HPLC analysis Moving phase consists of 15%sodium acetate buffer (5 mM/L, pH=3.75) and 85%ACN, with flow rate of 1.3 mL per min, an electrical chemical detector (ECD (electrochemical detector), Coulochem II, ESA) is used for the detection (E 1 =200mv, E2=400mv, E=500mv).
(3) Preparation of the standard solution The Nalbuphine that was dissolved in ACN was diluted to the concentration of 5, 10, 20, 50, 100, 200, 500, 1000, 2000, and 3000 ng/mL with serum.
Prepare the standard solution of various concentrations according to protocols described in step (1) "sample preparation". After HPLC analysis, obtain a corrected curve by plotting HPLC reading of nalbuphine wave heights against its relative concentration. Analyze the standard deviation (SD), coefficient of variance (%CV), and %error to examine the accuracy.
Result:
Table 7 shows the changes of nalbuphine in the blood from a pharmacokinetic point of view. There are significantly different Tmax, AUC, Cmax, CL/F, and V/F between the experimental and control sets. As shown in Table 7, the Tmax is 25 5min and Cmax is 2582.3 906.6 ng/ml in SD rat after being administered with both 100 mg/Kg nalbuphine and 4 mg/Kg capillarisin orally. In comparison, the Tmax is 97 36 min and Cmax is 79.31 18 ng/ml in the control group which was treated with 100 mg/Kg nalbuphine only.
The above results indicated that due to the inhibitive effect of capillarisin on UGT2B, the adsorption of nalbuphine had a 30-fold increase from the original concentration that was orally administered; and the absolute bio-availability increased to 108% from the original 5%.
On the other hand, no significant difference in MRT, k, t1/2 value was observed between the sample and the control. It indicates the administration of capillarisin has no influence on the metabolism of nalbuphine.
Figure 1 shows the temporal effect of capillarisin on the blood nalbuphine concentration after SD rats were given nalbuphine orally. According to Figure 1, the concentration of serum nalbuphine in the experimental set was 32.68 times higher than in the control set, at 0.25 hour after administration. The difference in the nalbuphine concentration diminishes by time.
Table 7 Pharmacokinetic analysis of orally administered nalbuphine in the control set (without capillarisin) and experimental set (with capillarisin) PK Coefficient (unit) Control (n=6) Experiment (n=6) Nalbuphine Nalbuphine + capillarisin (Mean SE) (Mean SE) Cmax * (ng/mL) 79 18 2582 906 Tmax (min) 97 36 25 5 AUC ' (0-t) (min*ng/mL) 21430 8823 218248 AUC * (total) (min*ng/mL) 24356 8865 244071 k (I /min) 0.0027 0.0007 0.0027 0.0006 t 1/2 (min) 332 62 310 59 MRT (mm) 496 90 316 103 CL/F ' (mL/min/kg) 5838 1049 826 364 V/F * (mL/kg) 2919123 Note: * indicates < 0.05; ** indicates p 5_ 0.01 Experiment 4. Effects of UGT2B inhibitor on the concentration of intravenously administered nalbuphine Material and methods:
The experiment follows the same protocol as described in the "material and methods" section of "Experiment 3", but an insertion of a catheter tube in the carotid artery was added, in addition to those procedures described in previous "3.
Methods" step. Such a design is for the purpose of delivering the drug via the vein while obtaining blood samples from the artery. The insertion of a tube is similar to the step ii in "Experiment 3", but a special attention is necessary to avoid blood loss by clamping the artery near the heart during the insertion of the tubing. Just insert about 2.5 cm into the artery will be enough.
Take 0.3 mL blood sample from the PE-50 catheter, at 15, 20, 30, 45, 60, 90, 120, and 180 minutes after the drug was given to SD rats, and analyze the concentration of nalbuphine in the blood in both the experimental and control sets.
Result:
Table 8 depicts the change of nalbuphine in blood, from the pharmacokinetic point of view. There are obvious differences in AUC, Cmax, CL/F, and V/F between the control and the experimental animals. The highest concentration in blood (Cmax) reaches 365 119 ng/ml, after SD rat was given 100 mg/Kg nalbuphine and 4mg capillarisin intravenously. While in the control animals, the Cmax is a relatively lower 154 30 ng/ml with only 100 mg/Kg nalbuphine was given.
The above result demonstrates that intravenous capillarisin administration inhibits UCT2B. it increases the nalbuphine concentration to 32.68 times higher than in the control animals, and enhances absolute bio-availability by 2.7 0.4%.
In comparison, the oral administration of nalbuphine to SD rats with and without the addition of capillarisin will increase the absolute bio-availabilities to 127.85 36.41% and 12.759 4.64% respectively.
Figure 2 shows the temporal effect of capillarisin on the concentration of nalbuphine in blood after SD rats were given nalbuphine intravenously.
The difference in the nalbuphine concentration between the control and experimental animals increases gradually by time. After 180 minutes, the serum nalbuphine concentration in the experimental animals was 2.37 times that of the control animals.
Table 8 Pharmacokinetic analysis of intravenous administration of nalbuphine without capillarisin (control sets) and with capillarisin (experimental sets) PK Coefficient (unit) Control (n=6) Experiment (n=6) Nalbuphine Nalbuphine + capillarisin (Mean SE) (Mean SE) Cmax (ng/mL) 154 30 365 119 AUC (0-t) (min*ng/mL) 1731 295 5862 1188 AUC ' (total) (min*ng/mL) 1909 330 7135 1218 (1/min) 0.016 0.004 0.017 0.008 t 1/2 (min) 77 29 63 11 MRT (min) 59 12 89 17 CL/F * (mL/min/kg) 843 235 204 34 V/F * (mL/kg) 42194 6492 19379 6475 Note: * indicates < 0.05; ** indicates p 0.01 Experiment 5. Comparison of the effect of UGT2B inhibitor on the orally and intravenously administered nalbuphine concentrations Material and method:
This experiment uses the same "material and method" as described in Experiments 3 and 4.
Deliver nalbuphine orally and intravenously to control animals, and nalbuphine and capillarisin orally to experimental animals. Take 0.3 ml blood samples from the PE-50 tubing to analyze the concentration of nalbuphine in the serum.
Result:
Figure 3 shows the changes of the nalbuphine concentration in SD rats at different time, after nalbuphine was orally and intravenously given to the control group while nalbuphine and capillarisin were orally given to the experiment group.
The absorption of orally administered drugs is affected by three factors:
adsorption in the gastroenterological tract, first-pass effect, and other metabolism;
while the intravenous route is affected mainly by metabolism other than the first-pass effect. Comparing the animals that were orally given inhibitor (experiment group) with those intravenously given drug without inhibitor (control group), as shown in Figure 3, the oral absorption is significantly improved with the presence of the inhibitor. Its absolute bio-availability increases from 5 % to 108 %.
In addition, the AUC values are similar in both sets of animals, indicating the addition of the inhibitor enhances the oral absorption of nalbuphine. [Note:
compare values in Table 5 and 6, the AUC value of orally administered nalbuphine and capillarisinin in Table 5 was 244071 69510, while the AUC
value in the control set (intravenous administration) was 7135 1218. They seem to be inconsistent with the above conclusion. The discrepancy is caused by the difference in quantity: when given the nalbuphine through oral route, the dose was 100 mg / Kg, while the intravenous dose was 1 mg / Kg].
Many changes and modifications in the above described embodiment of the invention can, of course, be carried out without departing from the scope thereof.
Accordingly, to promote the progress in science and the useful arts, the invention is disclosed and is intended to be limited only by the scope of the appended claims.
4. Measurement of the concentration of nalbuphine (1) Sample preparation Place 0.1 mL serum in a 10 mL test tube and quickly transfer it to an ice bath. Add 50 pL internal standard (buprenorphine 5 pg/mL) and 05 mL sodium carbonate buffer (0.5 mole/L, pH=9.25) and mixed well. Extract the serum with mL n-hexane and isoamyl alcohol mixture (9:1 (v/v)), and shake for 20 min.
Centrifuge at 1,080xg speed at 4 C for 15 min, then place it in a -80 C
freezer until the water layer froze. Transfer the organic solvent layer into another clean test tube, lyophylized until dried. Add 100pL ACN to dissolve the dried material, auto-pipette 50pL and applied to HPLC for analyzing the concentration.
(2) Condition for HPLC analysis Moving phase consists of 15%sodium acetate buffer (5 mM/L, pH=3.75) and 85%ACN, with flow rate of 1.3 mL per min, an electrical chemical detector (ECD (electrochemical detector), Coulochem II, ESA) is used for the detection (E 1 =200mv, E2=400mv, E=500mv).
(3) Preparation of the standard solution The Nalbuphine that was dissolved in ACN was diluted to the concentration of 5, 10, 20, 50, 100, 200, 500, 1000, 2000, and 3000 ng/mL with serum.
Prepare the standard solution of various concentrations according to protocols described in step (1) "sample preparation". After HPLC analysis, obtain a corrected curve by plotting HPLC reading of nalbuphine wave heights against its relative concentration. Analyze the standard deviation (SD), coefficient of variance (%CV), and %error to examine the accuracy.
Result:
Table 7 shows the changes of nalbuphine in the blood from a pharmacokinetic point of view. There are significantly different Tmax, AUC, Cmax, CL/F, and V/F between the experimental and control sets. As shown in Table 7, the Tmax is 25 5min and Cmax is 2582.3 906.6 ng/ml in SD rat after being administered with both 100 mg/Kg nalbuphine and 4 mg/Kg capillarisin orally. In comparison, the Tmax is 97 36 min and Cmax is 79.31 18 ng/ml in the control group which was treated with 100 mg/Kg nalbuphine only.
The above results indicated that due to the inhibitive effect of capillarisin on UGT2B, the adsorption of nalbuphine had a 30-fold increase from the original concentration that was orally administered; and the absolute bio-availability increased to 108% from the original 5%.
On the other hand, no significant difference in MRT, k, t1/2 value was observed between the sample and the control. It indicates the administration of capillarisin has no influence on the metabolism of nalbuphine.
Figure 1 shows the temporal effect of capillarisin on the blood nalbuphine concentration after SD rats were given nalbuphine orally. According to Figure 1, the concentration of serum nalbuphine in the experimental set was 32.68 times higher than in the control set, at 0.25 hour after administration. The difference in the nalbuphine concentration diminishes by time.
Table 7 Pharmacokinetic analysis of orally administered nalbuphine in the control set (without capillarisin) and experimental set (with capillarisin) PK Coefficient (unit) Control (n=6) Experiment (n=6) Nalbuphine Nalbuphine + capillarisin (Mean SE) (Mean SE) Cmax * (ng/mL) 79 18 2582 906 Tmax (min) 97 36 25 5 AUC ' (0-t) (min*ng/mL) 21430 8823 218248 AUC * (total) (min*ng/mL) 24356 8865 244071 k (I /min) 0.0027 0.0007 0.0027 0.0006 t 1/2 (min) 332 62 310 59 MRT (mm) 496 90 316 103 CL/F ' (mL/min/kg) 5838 1049 826 364 V/F * (mL/kg) 2919123 Note: * indicates < 0.05; ** indicates p 5_ 0.01 Experiment 4. Effects of UGT2B inhibitor on the concentration of intravenously administered nalbuphine Material and methods:
The experiment follows the same protocol as described in the "material and methods" section of "Experiment 3", but an insertion of a catheter tube in the carotid artery was added, in addition to those procedures described in previous "3.
Methods" step. Such a design is for the purpose of delivering the drug via the vein while obtaining blood samples from the artery. The insertion of a tube is similar to the step ii in "Experiment 3", but a special attention is necessary to avoid blood loss by clamping the artery near the heart during the insertion of the tubing. Just insert about 2.5 cm into the artery will be enough.
Take 0.3 mL blood sample from the PE-50 catheter, at 15, 20, 30, 45, 60, 90, 120, and 180 minutes after the drug was given to SD rats, and analyze the concentration of nalbuphine in the blood in both the experimental and control sets.
Result:
Table 8 depicts the change of nalbuphine in blood, from the pharmacokinetic point of view. There are obvious differences in AUC, Cmax, CL/F, and V/F between the control and the experimental animals. The highest concentration in blood (Cmax) reaches 365 119 ng/ml, after SD rat was given 100 mg/Kg nalbuphine and 4mg capillarisin intravenously. While in the control animals, the Cmax is a relatively lower 154 30 ng/ml with only 100 mg/Kg nalbuphine was given.
The above result demonstrates that intravenous capillarisin administration inhibits UCT2B. it increases the nalbuphine concentration to 32.68 times higher than in the control animals, and enhances absolute bio-availability by 2.7 0.4%.
In comparison, the oral administration of nalbuphine to SD rats with and without the addition of capillarisin will increase the absolute bio-availabilities to 127.85 36.41% and 12.759 4.64% respectively.
Figure 2 shows the temporal effect of capillarisin on the concentration of nalbuphine in blood after SD rats were given nalbuphine intravenously.
The difference in the nalbuphine concentration between the control and experimental animals increases gradually by time. After 180 minutes, the serum nalbuphine concentration in the experimental animals was 2.37 times that of the control animals.
Table 8 Pharmacokinetic analysis of intravenous administration of nalbuphine without capillarisin (control sets) and with capillarisin (experimental sets) PK Coefficient (unit) Control (n=6) Experiment (n=6) Nalbuphine Nalbuphine + capillarisin (Mean SE) (Mean SE) Cmax (ng/mL) 154 30 365 119 AUC (0-t) (min*ng/mL) 1731 295 5862 1188 AUC ' (total) (min*ng/mL) 1909 330 7135 1218 (1/min) 0.016 0.004 0.017 0.008 t 1/2 (min) 77 29 63 11 MRT (min) 59 12 89 17 CL/F * (mL/min/kg) 843 235 204 34 V/F * (mL/kg) 42194 6492 19379 6475 Note: * indicates < 0.05; ** indicates p 0.01 Experiment 5. Comparison of the effect of UGT2B inhibitor on the orally and intravenously administered nalbuphine concentrations Material and method:
This experiment uses the same "material and method" as described in Experiments 3 and 4.
Deliver nalbuphine orally and intravenously to control animals, and nalbuphine and capillarisin orally to experimental animals. Take 0.3 ml blood samples from the PE-50 tubing to analyze the concentration of nalbuphine in the serum.
Result:
Figure 3 shows the changes of the nalbuphine concentration in SD rats at different time, after nalbuphine was orally and intravenously given to the control group while nalbuphine and capillarisin were orally given to the experiment group.
The absorption of orally administered drugs is affected by three factors:
adsorption in the gastroenterological tract, first-pass effect, and other metabolism;
while the intravenous route is affected mainly by metabolism other than the first-pass effect. Comparing the animals that were orally given inhibitor (experiment group) with those intravenously given drug without inhibitor (control group), as shown in Figure 3, the oral absorption is significantly improved with the presence of the inhibitor. Its absolute bio-availability increases from 5 % to 108 %.
In addition, the AUC values are similar in both sets of animals, indicating the addition of the inhibitor enhances the oral absorption of nalbuphine. [Note:
compare values in Table 5 and 6, the AUC value of orally administered nalbuphine and capillarisinin in Table 5 was 244071 69510, while the AUC
value in the control set (intravenous administration) was 7135 1218. They seem to be inconsistent with the above conclusion. The discrepancy is caused by the difference in quantity: when given the nalbuphine through oral route, the dose was 100 mg / Kg, while the intravenous dose was 1 mg / Kg].
Many changes and modifications in the above described embodiment of the invention can, of course, be carried out without departing from the scope thereof.
Accordingly, to promote the progress in science and the useful arts, the invention is disclosed and is intended to be limited only by the scope of the appended claims.
Claims (7)
1. A pharmaceutical composition comprising:
an opioid;
an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, .beta.-naphthoflavone, .alpha.-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, puerarin, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, polyethylene glycol (PEG) 400, PEG 2000, PEG
4000, Tween ® 20, Tween® 60, Tween® 80, BRIJ® 58, BRIJ® 76, Pluronic®F68, Pluronic®F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
an opioid;
an Uridine diphosphate ( UDP ) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, .beta.-naphthoflavone, .alpha.-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, puerarin, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, polyethylene glycol (PEG) 400, PEG 2000, PEG
4000, Tween ® 20, Tween® 60, Tween® 80, BRIJ® 58, BRIJ® 76, Pluronic®F68, Pluronic®F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
2. The pharmaceutical composition of claim 1, wherein the opioid is (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrexone, naltrindole, nalbuphine, buprenorphine or a mixture thereof.
3. The pharmaceutical composition of claim 2, wherein the opioid is nalbuphine.
4. The pharmaceutical composition of any one of claims 1 to 3, which is intended for intravenous administration.
5. The pharmaceutical composition of any one of claims 1 to 3, which is intended for oral administration.
6. A pharmaceutical composition comprising a mixture intended for oral administration, the mixture comprising:
an opioid being (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrexone, naltrindole, nalbuphine, buprenorphine, or a mixture thereof;
an Uridine diphosphate (UDP) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, .beta.-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, terpineol, (+)-limonene, .beta.-myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, polyethylene glycol (PEG) 400, PEG
2000, PEG 4000, Tween® 20, Tween® 60, Tween® 80, BRIJ ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
an opioid being (-)-morphine, naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrexone, naltrindole, nalbuphine, buprenorphine, or a mixture thereof;
an Uridine diphosphate (UDP) -glucuronosyltransferases 2B (UGT2B) inhibitor, the inhibitor being a free base or a pharmaceutically acceptable salt of capillarisin, isorhamnetin, .beta.-naphthoflavone, a-naphthoflavone, hesperetin, swertiamarin, eriodictyol, baicalin, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, genistein, ethyl myristate, umbelliferone, terpineol, (+)-limonene, .beta.-myrcene, cineole, apigenin, ursolic acid, gallic acid, glycyrrhizin, protocatechuic acid, polyethylene glycol (PEG) 400, PEG
2000, PEG 4000, Tween® 20, Tween® 60, Tween® 80, BRIJ ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, or a mixture thereof; and a pharmaceutically acceptable inert ingredient.
7. The pharmaceutical composition of claim 6, wherein the opioid is nalbuphine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/028,615 US20060040875A1 (en) | 2004-01-08 | 2005-01-05 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
US11/028,615 | 2005-01-05 | ||
PCT/CN2005/002167 WO2006072203A1 (en) | 2005-01-05 | 2005-12-13 | Inhibitor or promoter of uridinediphosphate glucuronosyltransferase2b (ugt2b) |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2593140A1 CA2593140A1 (en) | 2006-07-13 |
CA2593140C true CA2593140C (en) | 2013-08-13 |
Family
ID=36647410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2593140A Active CA2593140C (en) | 2005-01-05 | 2005-12-13 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP5133064B2 (en) |
CN (1) | CN100571696C (en) |
CA (1) | CA2593140C (en) |
WO (1) | WO2006072203A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI397413B (en) * | 2010-10-29 | 2013-06-01 | Nat Defense Education And Res Foundation | New administration route, new dosage form and new dosage of nalbuphine |
EP2664919A1 (en) * | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | A method for identifying the AhR receptor ligands having a therapeutic sebosuppressive activity |
CN103143021A (en) * | 2013-03-21 | 2013-06-12 | 中国药科大学 | Application of PPAR alpha-UGT (peroxisome proliferator activated receptor alpha-uridine diphosphate glucuronosyl transferase) pathway inhibitor in treating inflammatory bowel diseases |
BR112015025684A2 (en) * | 2013-04-08 | 2017-07-18 | Indivior Uk Ltd | method for providing one or more opioid (s) to an individual, dosage form, method for treating or preventing pain and method for treating or preventing addiction or addiction |
CN107427489A (en) * | 2014-08-22 | 2017-12-01 | 财团法人教育研究基金会 | For treating medicine and the application of NASH disease |
CN106191017B (en) * | 2015-05-25 | 2021-12-07 | 中国医学科学院药物研究所 | Uridine-5' -diphosphate apiose/xylose synthetase derived from ornithogalum caudatum, nucleotide sequence and application thereof |
CN104876951B (en) * | 2015-05-26 | 2017-05-03 | 西安交通大学 | Preparation method for puerarin morphine |
CN104940190A (en) * | 2015-07-13 | 2015-09-30 | 江苏天晟药业有限公司 | Application of puerarin to preparing pain easing medicine |
CN106008483A (en) * | 2016-06-08 | 2016-10-12 | 沈阳药科大学 | Preparation and application of isovitexin |
CN109512829A (en) * | 2017-09-19 | 2019-03-26 | 复旦大学 | Luteolin 7-O- glucoside is preparing the application in anti-hepatic-B virus medicine |
US11131677B2 (en) | 2018-04-10 | 2021-09-28 | University Of Washington | Methods for treating testosterone deficiency in men and methods for precise dosing of UGT2B17 substrate drugs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562298A (en) * | 1982-10-25 | 1985-12-31 | Chemex Pharmaceuticals, Inc. | Optically active nordihydroguaiaretic acid and intermediates |
JPH06172195A (en) * | 1992-12-03 | 1994-06-21 | Tsumura & Co | Udp-glucuronyl transferase inhibitor |
GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
WO2003051313A2 (en) * | 2001-12-18 | 2003-06-26 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
JP4233796B2 (en) * | 2002-02-22 | 2009-03-04 | ハウスウェルネスフーズ株式会社 | Indigoid-containing glucuronosyltransferase inducer |
TWI287990B (en) * | 2004-01-08 | 2007-10-11 | Nat Defense Medical Ct | Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B) |
-
2005
- 2005-12-13 CN CNB2005101304861A patent/CN100571696C/en active Active
- 2005-12-13 WO PCT/CN2005/002167 patent/WO2006072203A1/en not_active Application Discontinuation
- 2005-12-13 JP JP2007549784A patent/JP5133064B2/en active Active
- 2005-12-13 CA CA2593140A patent/CA2593140C/en active Active
-
2011
- 2011-05-13 JP JP2011108637A patent/JP2011190267A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2011190267A (en) | 2011-09-29 |
WO2006072203A1 (en) | 2006-07-13 |
CA2593140A1 (en) | 2006-07-13 |
JP2008526788A (en) | 2008-07-24 |
CN1820743A (en) | 2006-08-23 |
JP5133064B2 (en) | 2013-01-30 |
CN100571696C (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2593140C (en) | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b) | |
US9415034B2 (en) | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | |
US6180666B1 (en) | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds | |
US9616033B2 (en) | Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities | |
Marena et al. | Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders | |
Kamei et al. | Pharmacokinetic and pharmacodynamic profiles of the antitussive principles of Glycyrrhizae radix (licorice), a main component of the Kampo preparation Bakumondo-to (Mai-men-dong-tang) | |
US20030215462A1 (en) | Use of UGT inhibitors to increase bioavailability | |
Ma et al. | Disposition of flavonoids impacts their efficacy and safety | |
Chen et al. | The exposure of luteolin is much lower than that of apigenin in oral administration of Flos Chrysanthemi extract to rats | |
Xia et al. | A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut | |
US20160051536A1 (en) | Compositions to alleviate presystemic metabolism of opioids | |
US20060040875A1 (en) | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | |
Chiang et al. | Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats | |
US7169763B2 (en) | Cytochrome P450 3A inhibitors and enhancers | |
Lu et al. | Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes | |
Li et al. | Characteristics of delayed excretion of flavonoids in human urine after administration of Shosaiko-to, a herbal medicine | |
Untergehrer et al. | Identification of phase-II metabolites from human serum samples after oral intake of a willow bark extract | |
US20230210931A1 (en) | Tannin-based antiproliferative pharmaceutical | |
WO2001003695A1 (en) | Improvement of bioavailability with vitamin c fatty acid esters | |
Wurglics et al. | Pharmacokinetics and biopharmaceuticals | |
Wang | Transporter-mediated flavonoid-drug interactions: In vitro and in vivo | |
Cott | 8 Interaction of herbs with other medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |